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The neuropathological hallmarks of Alzheimer’s disease (AD) include senile plaques of
β-amyloid (Aβ) peptides (a cleavage product of the Amyloid Precursor Protein, or APP)
and neurofibrillary tangles (NFT) of hyperphosphorylated Tau protein assembled in paired
helical filaments (PHF). NFT pathology is important since it correlates with the degree of
cognitive impairment in AD. Only a small proportion of AD is due to genetic variants,
whereas the large majority of cases (∼99%) is late onset and sporadic in origin. The
cause of sporadic AD is likely to be multifactorial, with external factors interacting with
biological or genetic susceptibilities to accelerate the manifestation of the disease. Insulin
dysfunction, manifested by diabetes mellitus (DM) might be such factor, as there is
extensive data from epidemiological studies suggesting that DM is associated with an
increased relative risk for AD. Type 1 diabetes (T1DM) and type 2 diabetes (T2DM) are
known to affect multiple cognitive functions in patients. In this context, understanding
the effects of diabetes on Tau pathogenesis is important since Tau pathology show a
strong relationship to dementia in AD, and to memory loss in normal aging and mild
cognitive impairment. Here, we reviewed preclinical studies that link insulin dysfunction
to Tau protein pathogenesis, one of the major pathological hallmarks of AD. We found
more than 30 studies reporting Tau phosphorylation in a mouse or rat model of insulin
dysfunction. We also payed attention to potential sources of artifacts, such as hypothermia
and anesthesia, that were demonstrated to results in Tau hyperphosphorylation and could
major confounding experimental factors. We found that very few studies reported the
temperature of the animals, and only a handful did not use anesthesia. Overall, most
published studies showed that insulin dysfunction can promote Tau hyperphosphorylation
and pathology, both directly and indirectly, through hypothermia.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder charac-
terized by a progressive loss of memory and a decline of cognitive
functions. With aging population as a main risk factor (Harman,
2002), this pathology becomes one of the most frequent neurode-
generative diseases and one of the top public health economic
concerns since more than 35 million people worldwide were
affected in 2010 (Querfurth and Laferla, 2010).
Amyloid plaques and neurofibrillary tangles (NFT) are the two
histopathological hallmarks of AD. Amyloid plaques are com-
posed of extracellular aggregates of the β-amyloid peptide (Aβ)
(Glenner and Wong, 1984; Selkoe, 2001), while NFT are com-
posed of abnormally phosphorylated Tau protein, assembled into
paired helical filaments (PHF) (Brion et al., 1985; Grundke-Iqbal
et al., 1986; Buée et al., 2000).
Only rare cases of early onset Familial Alzheimer’s Disease
(FAD) are caused by mutations in the amyloid precursor protein
(APP) or presenilin genes. By contrast, the etiology of the vast
majority of cases, which are sporadic late onset AD (LOAD), is
still misunderstood due to its multifactorial components involv-
ing both genetic and environmental factors. Two other common
syndromes in the elderly are associated with aging, i.e., diabetes
mellitus (DM) and impaired glucose tolerance. It is estimated
that, in 2030, the number of diabetic people over 64 years old will
exceed 82 million cases in developing countries, and 48 million
cases in developed countries (Wild et al., 2004).
To date, there is increasing evidence supporting a link between
AD and insulin dysfunction (Frolich et al., 1999; Gasparini et al.,
2002; Craft and Watson, 2004; De La Monte et al., 2009; Sims-
Robinson et al., 2010). For example, compared to age-matched
controls, AD brains show low concentrations of insulin accompa-
nied by an increase in the number of insulin receptors (Frolich
et al., 1999; Craft and Watson, 2004). Moreover, numerous
population-based studies have examined the association between
AD and insulin dysfunction. Some studies found no associa-
tion (Arvanitakis et al., 2006; Thambisetty et al., 2013); while,
interestingly, others suggest that hyperglycemia, impaired insulin
secretion, glucose intolerance and insulin resistance are all associ-
ated with increased risk of AD (Luchsinger et al., 2004; Ronnemaa
et al., 2008; Crane et al., 2013a). Thus, higher AD incidences rates
were detected in elderly diabetic patients (Leibson et al., 1997; Ott
et al., 1999; Luchsinger et al., 2004; Xu et al., 2004; Ronnemaa
et al., 2008), and reduced mental skills have been observed in dia-
betic children (Northam et al., 2001; Schoenle et al., 2002; Fox
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et al., 2003; Dahlquist and Kallen, 2007; and for review, see Roriz-
Filho et al., 2009). All this evidence has prompted the hypothesis
that AD might be a form of brain diabetes (Hoyer, 1998; De La
Monte et al., 2006).
In this article, we will review both in vitro and animal find-
ings reporting a correlation between diabetes and Tau pathology,
one of the major neuropathological hallmarks of AD. We will also
focus on the mechanisms that might link insulin dysfunction to
Tau pathology.
TAU PROTEIN
STRUCTURE AND FUNCTION
Tau is a microtubule-associated protein that is abundant in the
central nervous system (CNS) and expressed mainly in axons.
In the human brain, Tau proteins constitute a family of six
isoforms, ranging from 352 to 441 amino acids, all derived
from single gene by alternative splicing (Goedert et al., 1989).
The amino-terminal region of Tau, also called the “projection
domain,” project from the microtubule (MT) space to inter-
act with the plasma membrane and is essential for determining
axonal diameter (Chen et al., 1992). The carboxy-terminal region
is characterized by the presence of 3 or 4 repeats that mediate
the properties of Tau to stabilize MT and promote their poly-
merization (Weingarten et al., 1975; Cleveland et al., 1977a,b;
Himmler et al., 1989; Butner and Kirschner, 1991; Gustke et al.,
1994). These functions are negatively regulated by phosphoryla-
tion at multiple sites in, and around, the MT binding domain
(for review, see Buée et al., 2000; Avila et al., 2004). Indeed, at
least 30 Ser/Thr potential Tau phosphorylation sites have been
described on Tau (Sergeant et al., 2008). Tau phosphorylation is
regulated by numerous Ser/Thr kinases and phosphatases; among
them glycogen synthase kinase-3β (GSK-3β) and protein phos-
phatase 2A (PP2A) are considered to be the major Tau kinase
and phosphatase in vivo, respectively (Planel et al., 2002; Tian and
Wang, 2002).
Intracellular aggregates of abnormally hyperphosphorylated
Tau characterize a group of neurodegenerative diseases called
“Tauopathies” (for review, see Buée et al., 2000). Tau hyperphos-
phorylation may lead to its aggregation in vitro (Alonso et al.,
2001; Sato et al., 2002) and is thought to induce NFT forma-
tion and neurodegeneration in AD brains (Trojanowski and Lee,
1994).
INTERACTION BETWEEN TAU AND AMYLOID PATHOLOGY
The second major neuropathological hallmark of AD are amy-
loid plaques, mainly composed of amyloid-β (Aβ), a peptide
of 39–43 amino acids generated in vivo by specific proteolytic
cleavage of the APP, a transmembrane glycoprotein (Hardy
and Higgins, 1992). It appears that soluble oligomeric Aβ forms,
rather than amyloid plaques, contribute to the cellular pathology
of the AD and correlate with the severity of cognitive impairment
in humans (Lue et al., 1999; and for review, see Laferla et al.,
2007).
To date, the interaction between Tau pathology and amyloid
plaques in AD remains unresolved. Several murine animal mod-
els combining the two types of lesions have been investigated to
better address this issue.
However, results have shown different possible types of
interaction between the two pathologies. Thus, it was reported
that injection of Aβ42 peptide potentiates Tau pathology in
a mouse model of Tauopathy overexpressing a mutant form
of the protein (Gotz et al., 2001). Similarly, double transgenic
APP/Tau mice show early Tau pathology in comparison to Tau
transgenic mice (Lewis et al., 2001; Perez et al., 2005; Ribe
et al., 2005; Terwel et al., 2008). Interestingly, cultured neu-
rons obtained from Tau−/− mice seem to be protected against
neuronal death and cytotoxicity induced by Aβ, suggesting that
Tau is crucial for Aβ-induced neurotoxicity (Rapoport et al.,
2002). These results were further supported in vivo, in ani-
mal studies combining both Tau−/− and APP transgenic mice
and showing that Tau reduction is protective against neurolog-
ical and behavioral deficits induced by Aβ (Palop et al., 2006;
Roberson et al., 2007). More importantly, this hypothesis is
further supported by numerous post-mortem neuropathological
studies showing that the pathway of Tau pathology is progres-
sive, sequential and hierarchical (Bierer et al., 1995; Braak et al.,
1999; Delacourte and Buée, 2000), whereas amyloid deposition
is diffuse, widespread and extremely heterogeneous (Braak et al.,
1999; Delacourte et al., 1999). Moreover, NFT formation was
found to be strongly correlated with the degree of dementia
and memory loss in AD brains, whereas Aβ was not (Braak
and Braak, 1991, 1997; Delacourte et al., 1999). These observa-
tions have led some authors to the hypothesis that Tau pathol-
ogy could be the major cause of cognitive decline in humans
(Wilcock and Esiri, 1982; Delaere et al., 1989; Arriagada et al.,
1992; Duyckaerts et al., 1997, 1998; Gomez-Isla et al., 1997;
Delacourte et al., 2002; Giannakopoulos et al., 2003; Guillozet
et al., 2003; Bretteville and Planel, 2008). These findings are
in accordance with numerous animal studies showing signifi-
cant impairment of cognitive functions, synaptic dysfunctions,
as well as altered hippocampal synaptic plasticity in different
transgenic mouse models of Tauopathies (Polydoro et al., 2009;
Hoover et al., 2010; Van Der Jeugd et al., 2011; Burnouf et al.,
2013).
INSULIN DYSFUNCTION
BASICS OF INSULIN SIGNALING
The insulin receptor (IR) is a hetero-tetrameric receptor com-
posed of two extracellular α-subunits that bind insulin, and
two transmembrane β-subunits that have intracellular tyrosine
kinase activity. The binding of insulin to the α-subunits of IR
leads to the activation of the β subunit via auto-phosphorylation.
When activated, IR phosphorylates insulin receptor substrate
(IRS) proteins, which then activate phosphoinositide-3 kinase
(PI3K). Two major signaling pathways are further activated by
PI3K: the mitogen-activated protein kinase (MAPK) pathway and
the Akt pathway (for review, see White, 1997; Taha and Klip,
1999). MAPK pathway is mainly involved in cell differentiation,
cell proliferation and cell death, whereas Akt signaling is impli-
cated in cell proliferation, cell growth, and protein synthesis (for
review, see Brazil and Hemmings, 2001; Le Roith and Zick, 2001;
Tremblay and Giguere, 2008). Akt further induces the phosphory-
lation of GSK-3β, rendering it inactive, which results in increase
of glycogen synthesis in the periphery. Thus, disruption of Akt
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signaling leads to the dephosphorylation of GSK-3β, and hence
to its activation; (for review, see Taha and Klip, 1999).
In insulin resistance that occurs in T2DM, the capacity of
insulin to induce all these phosphorylation cascades is signif-
icantly decreased. Muscle biopsies of insulin resistant subjects
revealed a reduction in the enzymatic activity and phosphoryla-
tion state of kinases and substrates involved in the IR signaling
pathway (for review, see Schulingkamp et al., 2000; White, 2003;
Pirola et al., 2004; Youngren, 2007). However, the site(s) of the
initial perturbation of signal transduction are far from clear.
INSULIN IN THE CNS
In the past, the brain was described as “an insulin insensitive
organ” (Goodner and Berrie, 1977). However, it is currently well
known that insulin and its receptors are widely present in the
CNS (Baskin et al., 1988; Lerorrtt et al., 1988; for review, see
Schulingkamp et al., 2000). Although the origin of brain insulin
is still a matter of debate, several evidence suggest that central
insulin is actively transported from periphery across the blood-
brain barrier (BBB) (Banks et al., 1997a,b), and might be also
produced locally by neurons in the brain (Devaskar et al., 1994).
The initial evidence of de novo insulin synthesis in the CNS
came from a report showing insulin immunoreactivity in adult
rat brain (Havrankova et al., 1978b). This evidence was later
confirmed by other studies showing insulin gene expression and
synthesis in cultured mammalian neurons (Schechter et al., 1988,
1990; Devaskar et al., 1994).
Interestingly, it was shown that high peripheral insulin concen-
trations acutely increase the levels of insulin in the brain and the
cerebrospinal fluid (CSF), whereas prolonged peripheral hyper-
insulinemia leads to a down-regulation of IRs in the BBB and
to a reduction in insulin transport into the brain (Wallum et al.,
1987).
IRs are selectively distributed in the brain. Thus, IRs mRNA
levels are highly concentrated in several brain areas including
the olfactory bulb, pyriform cortex, amygdala, hippocampus,
hypothalamus and the cerebellar cortex (Marks et al., 1991; Zhao
et al., 1999). Accordingly, immunohistochemistry studies revealed
that IRs are highly expressed in the olfactory bulb, hypothala-
mus, cerebral cortex, amygdala and hippocampus (Havrankova
et al., 1978a,b; Baskin et al., 1987; Marks and Eastman, 1990;
Marks et al., 1991; Unger et al., 1991; Zhao et al., 1999).
Differences between peripheral and central IRs are not well
understood, although some structural differences, mainly includ-
ing the molecular weight and antigenicity, have been noted
(Heidenreich et al., 1983; Heidenreich and Gilmore, 1985).
The expression of IRs in specific brain regions, particularly the
hippocampus and medial temporal cortex suggests that insulin is
implicated in memory processes (Singh et al., 1997; Zhao et al.,
1999; Duarte et al., 2012; De Felice, 2013). For example, it was
reported that both mRNA and protein levels of IRs are increased
in the rat brain following a spatial memory task, suggesting that
insulin might regulate normal memory function (Zhao et al.,
1999).
By contrast, several findings have showed that insulin dys-
function, e.g., chronic hyperinsulinemia, DMor insulin resistance
have a negative impact onmemory process and cognitive function
(Roriz-Filho et al., 2009; Sims-Robinson et al., 2010; Benedict
et al., 2012; Crane et al., 2013b).
Mechanisms by which insulin might influence memory are
reviewed elsewhere (Zhao and Alkon, 2001; Craft and Watson,
2004; Gerozissis, 2008; Freiherr et al., 2013). In brief, insulin
signaling was shown to regulate neuronal survival, neurotrans-
mission and synaptic activities (Zhao and Alkon, 2001). Insulin
might also regulate synaptic plasticity by modulating long-term
potentiation (LTP) (Zhao et al., 2010; Nistico et al., 2012), and
promoting long-term depression (LTD) (Van Der Heide et al.,
2005; Labouèbe et al., 2013), two major mechanisms involved in
learning and memory.
In this context, it was demonstrated that treatment with
insulin sensitizers (e.g., liragultide, pioglitazone) ameliorates cen-
tral insulin resistance (Han et al., 2013; Hu et al., 2013; Yang
et al., 2013), improves cognitive impairment (Han et al., 2013),
enhances synaptic plasticity (Han et al., 2013), and significantly
decreases levels of Tau phosphorylation in the rat brain (Hu et al.,
2013; Yang et al., 2013).
Interestingly, it was recently established that administration
of intranasal insulin is a non-invasive technique that leads to an
increase of insulin levels specifically in the CNS, without affect-
ing peripheral glucose and insulin levels (Reger et al., 2008a).
Thus, several clinical studies have demonstrated a beneficial effect
of intranasal insulin on memory and cognitive function in AD
patients (Reger et al., 2008a,b; Craft et al., 2012).
Therefore, although emerging evidence support a role of brain
insulin signaling in several complex CNS functions, additional
mechanistic studies are warranted to better elucidate the contri-
bution of insulin signaling in normal and diseased brains.
DIABETES MELLITUS
Diabetes mellitus (DM) is a chronic disease, marked by high levels
of blood glucose. It occurs in two main forms: type 1 and type 2
diabetes, that respectively represent about 5–10% and 90–95%, of
the total diabetes cases (CDC, 2008).
Type 1 diabetes mellitus
Type 1 diabetes mellitus (T1DM) was previously known as
Insulin-dependent DM (IDDM) or juvenile diabetes to distin-
guish it from type 2 diabetes mellitus (T2DM), which generally
has a later onset; however, the majority of new-onset type 1
diabetes is seen in adults (Naik and Palmer, 2007).
It is due to autoimmune destruction of the insulin-producing
β-cells resulting in low or no production of insulin hormone.
Thus, insulin therapy is absolutely required in patients with
T1DM (McCrimmon and Sherwin, 2010). However, one major
feared side effect of insulin therapy is iatrogenic hypoglycemia,
which might occur in almost 90% of all insulin treated patients
(Cryer, 1997, 2001, 2004; Cryer et al., 2003).
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM), previously known as non-
insulin dependent DM (NIDDM), was usually associated with
aging. About 40% of the population over 65 and 50% over 80
years of age have T2DM or impaired glucose tolerance, and half
of diabetic people are not diagnosed (Lamberts et al., 1997).
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However, T2DM is not a disease exclusively associated with old
age, as it is more and more diagnosed in young people as the
number of cases has risen in parallel with obesity. Today, there
are 382 million people with T2DM, and it is estimated that this
number will rise to 592 million by 2035 (IDF, 2013). In T2DM,
pancreas produces insulin, but, for reasons that remain unclear,
cells are unable to use it, a characteristic of insulin resistance eti-
ology. Thus, in a positive feedback loop, pancreas overproduces
insulin to overcome the resistance, leading to a hyperinsulinemia
in early phases of T2DM (Festa et al., 2006). Over time, the suffer-
ing pancreas becomes unable to produce enough insulin, leading
to hyperglycemia and insulin deficiency that accompany T2DM
in the end of its natural history (Defronzo, 2004).
IMPACT OF INSULIN DYSFUNCTION ON TAU
PHOSPHORYLATION
Over the last decade, there has been considerable interest on the
impact of insulin dysfunction and diabetes on Tau pathology.
It has been shown that insulin could regulate Tau phosphoryla-
tion in neuronal cells (Hong and Lee, 1997; Lesort et al., 1999;
Lesort and Johnson, 2000), which was confirmed by observations
of hyperphosphorylated Tau in mice showing abnormal insulin
levels in the brain (Schubert et al., 2003, 2004; Planel et al., 2004;
Schechter et al., 2005). Despite all these data, very little is known
about the effects of diabetes on Tau pathogenesis in vivo.
IN VITRO STUDIES
Observations from in vitro studies strongly suggest that Tau
phosphorylation might be regulated by insulin signaling through
a biphasic manner. Thus, short insulin treatment (<2–3min),
either in rat primary cortical neurons (Lesort and Johnson, 2000),
or in SH-SY5Y human neuroblastoma cells (Lesort et al., 1999),
leads to a rapid and transient Tau hyperphosphorylation at the
AT8 (Ser202/Thr205), AT180 (Thr231), PHF-1 (Ser396/Ser404) and
T3P (Ser396) epitopes (Lesort et al., 1999; Lesort and Johnson,
2000). By contrast, prolonged exposure to insulin, in both human
neuroblastoma cells (up to 60min of treatment) (Lesort et al.,
1999), and human neuronal NT2N cells (5min of treatment)
(Hong and Lee, 1997), results in a significant decrease in Tau
phosphorylation. Interestingly, all these studies have led to the
conclusion that the effects of insulin are mediated by GSK-3β
activity (Hong and Lee, 1997; Lesort et al., 1999; Lesort and
Johnson, 2000).
Therefore, insulin signaling plays an important role in the reg-
ulation of Tau phosphorylation, and this effect is correlated with
GSK-3β activity, further suggesting a key role of this kinase in Tau
pathology.
IN VIVO STUDIES
The specific effects of insulin dysfunction on Tau pathology are
not fully understood. Therefore, several animal models are cur-
rently used to investigate the impact of both T1DM and T2DM
on Tau phosphorylation.
T1DM and Tau phosphorylation
Models of T1DM used in the literature mainly mimic insulin
deficiency that characterizes human T1DM. These models can
develop T1DM either spontaneously, due to a specific genetic
background, or by treatment with a drug called Streptozotocin
(STZ).
STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyr-anose))
is a toxin synthesized by Streptomycetes achromogenes, that
specifically enters pancreatic β cells via the glucose transporter
GLUT2, and leads to cell death through DNA alkylation (Delaney
et al., 1995). Thus, it is widely used to induce insulin deficiency
associated to T1DM (Ganda et al., 1976), both in wild-type
background context and AD pathological animal models.
STZ-induced wild-type animal models. Using an extensive panel
of phospho-dependent antibodies that detect specific epitopes
on Tau protein, several animal studies have investigated the
impact of peripheral STZ treatment on Tau phosphorylation
in non-transgenic animals (Table 1). For example, we have
previously reported that STZ administration (200mg/Kg, i.p.)
resulted in a massive Tau hyperphosphorylation at the Tau-1
(Ser195/Ser198/Ser199/Ser202), pS199 (Ser199), PHF-1, AT8, AT180,
Ser422, Ser262, Ser356 and Ser400epitopes in the brain of non-
transgenic mice (Planel et al., 2007b). Other studies have con-
firmed our results of increased Tau phosphorylation following
STZ treatment either in mice (Clodfelder-Miller et al., 2006;
Jolivalt et al., 2008; Ke et al., 2009; Kim et al., 2009), or in
rats (Qu et al., 2011), and observed a further increase in Tau
phosphorylation at the AT270 (Thr181) and Thr212 epitopes
(Table 1).
Some of the phosphoepitopes detected are associated to par-
ticular functions during Tau pathology. For example, Ser422 is
associated with early pre-tangle formation and is characteristic
of abnormal, AD-like Tau phosphorylation (Augustinack et al.,
2002). AT8 is considered an early marker of Tau dysfunction
(Matsuo et al., 1994; Hasegawa et al., 1996; Bussière et al., 1999;
Augustinack et al., 2002), whereas PHF-1 is associated with late
paired helical filament andNFT formation (Bramblett et al., 1993;
Goedert et al., 1993, 1994). In addition, some phosphorylation
sites have been linked to specific aspects of Tau pathology such
as the sequestration of normal Tau (e.g., Thr231/Ser235) (Alonso
et al., 1997, 2004), the inhibition of Tau MT binding (e.g., Ser262)
(Biernat et al., 1993; Drewes et al., 1995), and the promotion of
Tau aggregation (e.g., Ser396, Ser422) (Gong and Iqbal, 2008).
Interestingly, we have shown that the massive Tau hyperphos-
phorylation in STZ treated mice was mostly, but not completely,
rescued by returning animals to normothermia, suggesting that
hypothermia was partially involved in STZ-mediated Tau hyper-
phosphorylation. We have previously demonstrated that Tau
phosphorylation can be induced by hypothermia (Planel et al.,
2004, 2007b). Moreover, we have shown that this mechanism
is mainly attributable to a direct and rapid inhibition of PP2A
activity in the brain (Planel et al., 2004).
In fact, hypothermia is a common outcome in experimental
diabetes (Shalaby et al., 1989; Kilgour and Williams, 1996, 1998)
and several human diabetic populations (Neil et al., 1986; Scott
et al., 1987).
In addition, Tau phosphorylation is known to be exquisitely
sensitive to temperature, increasing by 80% per degree Celsius
drop under 37◦C in mice (Planel et al., 2007a; Papon et al., 2011).
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It has to be mentioned that previous studies done in other lab-
oratories described above did not monitor the temperature of
animals and therefore it is likely that hypothermia could con-
tribute to the observed Tau hyperphosphorylation in these studies
(Clodfelder-Miller et al., 2006; Ke et al., 2009; Kim et al., 2009; Qu
et al., 2011).
Therefore, temperature control during Tau analysis experi-
ments in animal models is crucial to avoid artifactual hypother-
mic Tau hyperphosphorylation.
STZ-induced transgenic animal models. Beside studies per-
formed in a physiological context, several investigators have
addressed the impact of STZ treatment on Tau phosphorylation
and NFT formation in transgenic mouse models of AD (Table 1).
For example, Ke et al. have shown that insulin depletion increases
more significantly Tau phosphorylation at multiple epitopes in
mice that overexpress P301L mutant human Tau, and are prone
to develop NFT (Gotz et al., 2001). This suggests that experimen-
tal diabetes leads to advanced NFT formation, as well as early
neurofibrillar deposition in Tau transgenic mice (Ke et al., 2009).
Similarly, insulin deficiency enhances the severity of Tau phos-
phorylation in the hippocampi of APP transgenic mice, which are
characterized by the accumulation of the β-amyloid peptide and
high levels of Aβ-immunoreactive plaques (Jolivalt et al., 2010).
Therefore, it seems that STZ-induced T1DM recapitulate NFT
formation observed during of AD, and this effect is further wors-
ened when the induction is combined to genetic pre-disposition
to AD.
However, it is important to note that several studies from those
cited above have used anesthesia prior to sacrifice (Clodfelder-
Miller et al., 2006; Jolivalt et al., 2008, 2010; Ke et al., 2009; Kim
et al., 2009) (Table 1), which is known to enhance Tau phos-
phorylation (Planel et al., 2007a; Papon et al., 2011; Whittington
et al., 2011; Le Freche et al., 2012). This increase can be induced
either directly, through a pharmacological effect of the drug itself
(Whittington et al., 2011; Le Freche et al., 2012), or indirectly,
through anesthesia-induced hypothermia (Planel et al., 2007a).
Thus, further animal studies with temperature control are war-
ranted to separate the impact of hypothermia from that of insulin
dysfunction on Tau phosphorylation.
Animal models of spontaneous T1DM. Although several studies
have reported Tau hyperphosphorylation in STZ-induced animal
models, it is important to extend these findings to a model that
does not require a drug to induce T1DM, because, as we will see
later, if STZ reaches the brain in minute quantities, it can lead to
Tau hyperphosphorylation on its own.
Thus, we have investigated Tau hyperphosphorylation in the
non-obese diabetic (NOD) mouse, one of the most valuable
genetic animalmodels for T1DM (Leiter, 2001). Thesemice spon-
taneously develop T1DM at 13–25 weeks of age as a consequence
of selective destruction of insulin-producing β cells (Makino
et al., 1980). Interestingly, our data indicated that Tau hyper-
phosphorylation correlates with the appearance of spontaneous
diabetes in adult NOD mice, and this effect was exacerbated
when the mice became hypothermic as a consequence of dia-
betes. Interestingly, even in the absence of any deregulation in
the glucose metabolism, we have observed a slight increase in
Tau phosphorylation at Tau-1 and Ser422 epitopes in non-diabetic
adult NODmice. Moreover, the onset of diabetes (the appearance
of hyperglycemia and glycosuria) was correlated with an exten-
sive Tau hyperphosphorylation at the AT8, CP13 (Ser202), Ser262
and Ser422 epitopes in comparison to control. Furthermore, the
appearance of hypothermia further extended Tau hyperphospho-
rylation to PHF-1 and TG3 (Thr231) epitopes in diabetic NOD
mice (Papon et al., 2013), (Table 1).
Of note, Li et al. have also investigated Tau phosphorylation
in BB/Wor rats, another model of spontaneous T1DM. Although
these authors did not find any significant changes in the levels
of Tau phosphorylation at the Ser396 epitope (Li et al., 2007), it
should be mentioned that there was no report of the rats temper-
ature and that they were anesthetized, which could have masked
a potential elevation in Tau phosphorylation.
Thus, while our study demonstrated Tau hyperphosphoryla-
tion in NOD mice, additional studies should be done to our
results in other animal models of spontaneous T1DM.
The insulin knockout animal model. In addition to genetic and
STZ-induced animal models, the insulin knockout mouse model
(Insulin−/−) might also mimic insulin deficiency that character-
izes T1DM. These mice rapidly develop DM, show a dramatic
glycosuria, and die within 48 h (Duvillie et al., 1997).
Interestingly, Schechter and colleagues have investigated
the impact of insulin deficiency on Tau phosphorylation in
Insulin−/− mice. Thus, among all phospho-epitopes investigated,
these authors have observed a significant increase in Tau phos-
phorylation at the AT180 epitope, suggesting that insulin signal-
ing might affect Tau phosphorylation in vivo (Schechter et al.,
2005), (Table 1).
T2DM and Tau phosphorylation
Models of T2DMused in animal studiesmainly reproduce human
T2DM features, including obesity, hyperglycemia, hyperinsuline-
mia, and insulin resistance. These models develop T2DM either
spontaneously, or by using a variety of treatments including
special diets.
Animal models of spontaneous T2DM. Several genetic animal
models are used in the literature to address the impact of
genetic T2DM on AD pathogenesis (Ellis et al., 1998; Li et al.,
2007; Jolivalt et al., 2008; Takeda et al., 2010). These models
are mainly characterized by an impairment of leptin signaling,
by either lacking leptin (ob/ob mice) (Coleman, 1978), or car-
rying specific mutations in the leptin receptor (Bio-Breeding
Zucker Diabetic Rats/Wor (BBZDR/Wor) rats and db/db mice)
(Hummel et al., 1966; Tirabassi et al., 2004). Leptin is an
adipocyte-specific hormone that plays important role in satiety
and energy expenditure. It acts through the leptin receptor, a
single-transmembrane-domain receptor of the cytokine receptor
family. However, mechanisms by which leptin signaling leads to
the development of T2DM are not well understood.
Several studies have reported Tau hyperphosphorylation in rat
(Li et al., 2007; Jung et al., 2011, 2013) and mouse models (Kim
et al., 2009; Li et al., 2012a) of spontaneous T2DM. For example,
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Jung et al. have reported an increase in Tau phosphorylation at the
Tau-1, Thr212 (Jung et al., 2011, 2013), Thr231, Ser262 and Ser396
(Jung et al., 2013) epitopes in the chronic Otsuka Long Evans
Tokushima Fatty (OLETF) T2DM rat model, and these changes
were further increased with age (Jung et al., 2013). In addition,
Li and colleagues have also observed Tau hyperphosphorylation
at the Ser396 site in the cortex of BBZDR/Wor rat strain (Li
et al., 2007). These results were also confirmed in db/db mice
that showed Tau hyperphosphorylation at the AT8, Ser199, Ser202,
Ser396, and Ser422 epitopes (Kim et al., 2009; Li et al., 2012a)
(Table 1). However, since these animals were anesthetized prior
to sacrifice and their temperature was not reported, it would be
interesting to repeat these experiments in controlled conditions.
Animal models of induced T2DM. High fat diet (HFD) is com-
monly used to induce T2DM in animals. Moroz et al. have
reported that HFD increases body weight, reduces brain weight
and leads to brain insulin resistance, since mice fed with HFD
showed increased brain insulin gene expression paralleled with
decreased IR binding (Moroz et al., 2008). However, levels of both
phosphorylated and total Tau were not affected in the brain of
non-transgenic animals treated with HFD, although Tau mRNA
levels were significantly increased (Moroz et al., 2008). Similarly,
levels of total soluble and insoluble Tau, but not phospho-Tau
were increased in HFD fed 3xTg-AD transgenic mice, suggesting
that effects of HFD are modest on Tau phosphorylation (Julien
et al., 2010).
On the other hand, a recent study has demonstrated that HFD
leads to Tau phosphorylation in a model of Tauopathy treated
with HFD, in a manner independent of insulin resistance, sug-
gesting that, other obesity-related factors, might contribute to Tau
pathology (Leboucher et al., 2012).
Interestingly, Bhat and Thirumangalakudi have reported that
feeding mice with high-fat/cholesterol (HFC) diet also leads to
peripheral insulin resistance. Importantly, these authors showed
that HFC results in increased levels of Tau hyperphosphorylation
at the PHF-1 and Thr231 epitopes in the mice hippocampi (Bhat
and Thirumangalakudi, 2013).
It is difficult to draw conclusion from HFD treatments since
published results are so divergent. The reasons for these differ-
ences could include the composition of the diet, the duration
of the treatment, the background strains, the levels of con-
tamination of the animal facilities and, of course, confounding
hypothermia.
Insulin signaling impairment animal models. The group of
Schubert et al. have generated and explored a brain/neuron
insulin receptor knockout (NIRKO) mouse model that exhibit
a conditional inactivation of the IR gene in the CNS (Schubert
et al., 2004). These mice are mainly characterized by hyperin-
sulinemia, mild insulin resistance, obesity and reduced fertility
(Bruning et al., 2000), and might therefore represent a model
of T2DM. Central IR deficiency in these mice has resulted in a
significant increase of Tau phosphorylation at the AT180 epitope
(Schubert et al., 2004).
Another model of insulin signaling impairment that might
represent a model of T2DM is the IRS-2−/− mouse model.
These mice are insulin resistant and develop diabetes as a result
of impairment in survival and function of pancreatic β-cells
(Bruning et al., 1998; Withers et al., 1998, 1999; Kulkarni et al.,
1999; Michael et al., 2000). Schubert et al. have demonstrated
that IRS-2−/− mice exhibit Tau hyperphosphorylation at the
Ser202epitope (Schubert et al., 2003), (Table 1).
Therefore, animal models of insulin signaling dysfunction
have provided additional evidence that insulin plays crucial role
in the regulation of Tau phosphorylation in vivo.However, further
studies are needed to better understand mechanisms underlying
these effects.
T3DM and Tau phosphorylation
Data from T1DM and T2DM animal models strongly suggest
that insulin signaling plays a key role in modulating AD patho-
genesis. However, in almost all animal models cited above, Tau
pathology was investigated in a context of peripheral insulin
dysfunction. Therefore, animal models exhibiting specific alter-
ation of the central insulin function might be helpful to address
the role of brain insulin disruption in AD pathology. Thus, the
group of Hoyer and colleagues have suggested that rats treated
with intra-cerebroventricular (i.c.v.) STZ represent a sporadic AD
animal model characterized by a specific insulin-resistant brain
state (Nitsch and Hoyer, 1991; Duelli et al., 1994; Lannert and
Hoyer, 1998; Salkovic-Petrisic and Hoyer, 2007). Interestingly, de
la Monte et al have later proposed that AD might represent a spe-
cific form of brain diabetes and thus proposed the term of “type
3 diabetes” (T3DM) (De La Monte et al., 2006; Lester-Coll et al.,
2006). Importantly, this hypothesis is supported by a recent post-
mortem study demonstrating a state of brain insulin resistance in
human AD patients (Talbot et al., 2012).
In induced T1DM animal models, STZ is administrated
peripherally at high doses (55–200mg/Kg). However, in T3DM
rats, STZ is injected in the brain ventricles at doses of up
to 100 times lower than those used in systemic injections
(Nitsch and Hoyer, 1991; Duelli et al., 1994; Lannert and
Hoyer, 1998). Although it was shown that pancreatic archi-
tecture, as well as levels of both insulin and glucose are not
affected following central STZ treatment (De La Monte et al.,
2006; Lester-Coll et al., 2006), numerous studies have reported
that T3DM rat models exhibit several neurochemical, structural
and behavioral changes that are similar to cellular abnormali-
ties observed in AD brains. These changes include brain atrophy,
cell loss, neurodegeneration (De La Monte et al., 2006; Lester-
Coll et al., 2006), a decrease in glucose utilization notably in
the hippocampi and entorhinal cortices of treated rats (Duelli
et al., 1994), a reduction of energy metabolism (Lannert and
Hoyer, 1998; Prickaerts et al., 2000; Yun et al., 2000), an
impairment in learning and memory, as well as a significant
increase in oxidative stress (Sharma and Gupta, 2001; Veerendra
Kumar and Gupta, 2003; Ishrat et al., 2006; Pathan et al.,
2006).
The mechanism of action of central STZ is far from clear,
but some observations suggest that it might be similar to that
in the periphery. Indeed, GLUT2, the glucose transporter tar-
geted by peripheral STZ, was found to be regionally distributed
in the mammalian brain (Brant et al., 1993; Leloup et al., 1994;
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Ngarmukos et al., 2001). In addition, DNA damage was observed
in T3DM rat brains (Nitsch and Hoyer, 1991; Lannert and Hoyer,
1998).
The vast majority of studies that have investigated Tau
phosphorylation following i.c.v. STZ administration (ranging
from 1 to 3mg/Kg) were performed in non-transgenic ani-
mal models. Interestingly, all these studies have observed a
significant increase in Tau phosphorylation at several epi-
topes, notably AT8, PHF-1, Ser199, Ser202, Ser396, Ser404, Thr181,
Thr205, Thr212, and Tau-1(Chu and Qian, 2005; Salkovic-
Petrisic et al., 2006; Grunblatt et al., 2007; Deng et al., 2009;
Chen et al., 2011, 2013b; Li et al., 2012b; Du et al., 2013)
(Table 1).
Interestingly, Chen et al. have recently investigated the impact
of T3DM on Tau phosphorylation in the 3xTg-ADmouse model.
These authors demonstrated an increase in Tau phosphoryla-
tion at the Ser199/Ser202, 12E8 (Ser262/Ser356) and Ser422epitopes
(Chen et al., 2013b).
By contrast, Plascke et al. didn’t detect any increase in the level
of phosphorylated Tau in the brain of Tg2576 mice (Plaschke
et al., 2010).
Therefore, T3DM leads to several alterations resembling to
those found in human AD patients, further giving consis-
tent evidence that brain insulin resistance might be a central
event in AD. However, it should be noted that it remain diffi-
cult to conclude from all studies cited above because they are
quite heterogeneous, considering differences in the rat strain
used, the dose of STZ delivered, the age at STZ treatment and
brain regions investigated (for review, see Salkovic-Petrisic et al.,
2006).
MECHANISMS LINKING INSULIN DYSFUNCTION TO TAU
PATHOLOGY
KINASES ACTIVATION
The increased phosphorylation of Tau on many residues might
be attributable to the activation of multiple kinases. Among the
kinases able to phosphorylate Tau in vitro, GSK-3β is considered
to be themajor physiological and pathological Tau kinases (Planel
et al., 2002; Hernandez et al., 2013).
Studies that have addressed GSK-3β activation in diabetic
animal models (using antibodies detecting the phosphorylation
state either at the Ser9 inhibitory site, or the Tyr216 acti-
vation site of the kinase) have shown contradictory findings
(Table 1), thus making it difficult to conclude about the impli-
cation of this kinase in the correlation between diabetes and
Tau pathogenesis. Of note, we (Planel et al., 2007b), and others
(Clodfelder-Miller et al., 2006; Deng et al., 2009), have demon-
strated that GSK-3β is inhibited in STZ-induced T1DM mice,
and our data demonstrated that this inhibition can be attributed
to hypothermia (Planel et al., 2001), as GSK-3β S9 phospho-
rylation is a constant feature of hypothermia in mouse brain
during metabolic stress (Planel et al., 2004) or anesthesia (Planel
et al., 2007a). However, it is important to note that, even when
inhibited, GSK-3β is still participating to Tau hyperphosphory-
lation, as we previously demonstrated with lithium, a GSK-3β
inhibitor, in mice rendered hypothermic by starvation (Planel
et al., 2001).
PHOSPHATASES INHIBITION
Ser/Thr protein phosphatases (PP) are classified into five types,
PP1, PP2A, PP2B, PP2C, and PP5, on the basis of their substrate
specificities and sensitivity to specific activators and inhibitors
(Liu et al., 2005). Biochemical studies have demonstrated that
PP1, PP2A, PP2B (Calcineurin), and PP5 are involved in Tau
dephosphorylation (Gong et al., 1994; Tian and Wang, 2002).
Importantly, it is believed that PP2A is the major Tau phosphatase
in vivo (Gong et al., 2000; Planel et al., 2001, 2004, 2007a), with
PP2A, PP1, PP5, and PP2B contributing to 71, 11, 10 and 7%,
respectively, of the total Tau phosphatase activity in the brain (Liu
et al., 2005).
The analysis of different Tau phosphatases in diabetic animal
models is less documented in comparison to kinases (Table 1).
However, although several investigators have observed a decrease
only in the expression of PP2A in T2DM mice brains (Schubert
et al., 2003; Li et al., 2012a), we (Planel et al., 2007b), and others
(Clodfelder-Miller et al., 2006; Qu et al., 2011; Jung et al., 2013),
have reported that PP2A activity is inhibited in both T1DM and
T2DM animal models.
Interestingly, Deters and colleagues demonstrated that co-
expression of P301L mutant human Tau and a dominant nega-
tive form of PP2A in the brain of transgenic mice significantly
increases Tau hyperphosphorylation and NFT formation, sug-
gesting a crucial role for PP2A in regulating Tau pathology
(Deters et al., 2009). This finding is particularly important since
PP2A is inhibited in human AD patients and seems to be an
important factor in the progression of the disease (Gong et al.,
1993, 1995; Vogelsberg-Ragaglia et al., 2001).
Thus, PP2A seems to be a key protein in the link between
insulin dysfunction and AD. Extending analyses to other dia-
betic mousemodels or genetically modifiedmice will facilitate the
understanding of molecular mechanisms underlying PP2A func-
tion, and thus help for the identification of molecules that may
compromise the reversibility of Tau hyperphosphorylation.
INFLAMMATION
Several studies have shown that insulin dysfunction is associ-
ated with inflammation. In the periphery, insulin was shown to
modulate many aspects of the inflammatory process. Thus, at
low doses, insulin exerts anti-inflammatory effects (Dandona,
2002); whereas, during chronic hyperinsulinemia, insulin may
exacerbate inflammatory responses and increase markers of
oxidative stress (Krogh-Madsen et al., 2004). Specifically, it was
demonstrated that levels of proinflammatory cytokines, includ-
ing Interleukin-1 (IL-1), IL-6, and C-reactive protein (CRP) are
elevated in diabetic patients (Hak et al., 2001; Spranger et al.,
2003).
In the CNS, several animal studies have also associated insulin
dysfunction to inflammation. For example, a significant increase
in the number of glial fibrillary acidic protein (GFAP)-reactive
astrocytes (also known as astrogliosis) was reported in the hip-
pocampi of both NOD and STZ-induced mouse models (Saravia
et al., 2002).
In addition, T2DM was shown to aggravate vascular inflam-
mation in an AD mouse model, changes that can be related to
impaired central insulin signaling (Takeda et al., 2010). Notably,
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 9
El Khoury et al. Insulin and Tau
a study by Pistell et al. has established that different diet com-
position results in various inflammatory reactions in the brain.
Thus, these authors have demonstrated that HFD consumption
leads to a significant increase in the levels of proinflamma-
tory cytokines, chemokines as well as reactive astrocytosis and
microgliosis (Pistell et al., 2010). These data suggest that inflam-
mation might be tightly related to Tau hyperphosphorylation
observed during T2DM.
Moreover, brains of i.c.v.-STZ treated rats showed increased
levels of IL-1 and tumor necrosis factor-α (TNF-α) (Chen et al.,
2013a), as well as pronounced astrogliosis and microglial activa-
tion (Prickaerts et al., 1999; Chen et al., 2013a).
On the other hand, there is evidence that Tau pathology
is associated with neuroinflammation. Thus, IL-1, IL-6 as well
as nitric oxide have been shown to exacerbate Tau pathology
and NFT formation in vitro (Li et al., 2003; Quintanilla et al.,
2004; Saez et al., 2004). Moreover, Shepherd et al. have demon-
strated that microglial activation might contribute to Tau hyper-
phosphorylation and NFT formation in postmortem AD brains
(Shepherd et al., 2000; for review, see Arnaud et al., 2006).
Similarly, administration of lipopolysaccharide (LPS), which is a
bacterial endotoxin commonly used in animal studies to induce
systemic inflammation (Lien et al., 2000), significantly increases
Tau hyperphosphorylation in a triple transgenic mouse model of
AD (Kitazawa et al., 2005). In addition, Yoshiyama et al. have
demonstrated that microglial neuroinflammation precedes Tau
pathology in P301S transgenic mice (Yoshiyama et al., 2007).
Mechanisms by which neuroinflammation might contribute
to Tau pathology are not well elucidated. However, it is known
that one signaling pathway by which neurons and microglia
communicate is fractalkine (CX3CL1) and its cognate receptor
(CX3CR1). In the CNS, CX3CL1 is highly expressed in neu-
rons, whereas CX3CR1 is exclusively expressed in microglia cells
(Harrison et al., 1998). Therefore, Bhaskar et al. have suggested
that the CX3CL1/CX3CR1 pathway could modulate Tau pathol-
ogy, and that this effect might be dependent upon microglial-
derived IL-1-p38 MAPK signaling pathway (Bhaskar et al., 2010).
Overall, the link between insulin dysfunction, inflammation
(both peripheral and/or central), and Tau hyperphosphorylation
is unclear and would benefit from future research focus.
STRESS
Stress might represent another mechanistic link between insulin
dysfunction and Tau hyperphosphorylation. Indeed, it was
recently reported that stress leads to both peripheral and central
insulin resistance, as well as increased Tau hyperphosphoryla-
tion in the mouse brain. Notably, these authors have pointed a
central role of JNK (c-Jun N-Terminal Kinase), a major stress
signaling pathway (Solas et al., 2013). These results suggest that
insulin resistance might mediate Tau phosphorylation through
a stress-dependent mechanism. Further studies are required to
better understand this issue.
INSULIN SIGNALING: THE CONVERGING ROAD
Insulin signaling impairment in diabetic animal models
While impaired peripheral insulin signaling is well known in ani-
mal models of diabetes, there is conflicting evidence of central
insulin signaling dysfunction.
The phosphorylation levels of IRs were reported to be signifi-
cantly decreased in mice treated with systemic STZ (Jolivalt et al.,
2008, 2010), as well as in the insulin KO mouse model (Schubert
et al., 2004) (Table 1). By contrast, levels of the β subunit of IR
(IRβ) have shown contradictory findings; whereas Jung et al have
observed that IRβ levels are increased in the brain of the OLETF
T2DM rat model (Jung et al., 2011), Li et al. have reported a
significant decrease in IRβ levels in the cortex of spontaneous
T1DM, but not T2DM rats (Li et al., 2007). Similarly, the insulin
KO mouse model has revealed a decrease in the expression of IRβ
in the brain (Schechter et al., 2005).
Conflicting results have also been reported for Akt, a key kinase
implicated in the insulin-signaling pathway, and also known to
phosphorylate Tau in vitro (Ksiezak-Reding et al., 2003). Thus, a
significant reduction in the phosphorylation levels and the activ-
ity of Akt (Li et al., 2007; Qu et al., 2011) was reported in the brain
of both T1DM and T2DM animal models (Jolivalt et al., 2008,
2010; Qu et al., 2011; Bhat and Thirumangalakudi, 2013). By
contrast, several data showed augmented phosphorylation of Akt
and GSK-3β Ser9 (inhibitory phosphorylation) in NOD and STZ-
treated mice (Clodfelder-Miller et al., 2005, 2006; Planel et al.,
2007b). It is interesting to note that the rise in Akt and GSK-
3β Ser9 phosphorylation in both NOD and STZ-treated mice
is probably due to the inhibition of PP2A, as inhibitors of the
phosphatase upregulate the phosphorylation of the two kinases
(Andjelkovic et al., 1996; Planel et al., 2001). However, how
peripheral insulin dysfunction results in central PP2A inhibition
remains to be elucidated.
Moreover, Moroz et al. have demonstrated that HFD-induced
T2DM leads to an increase in mRNA levels of IRS-1 and IRS-
4 in the brain of non-transgenic mice (Moroz et al., 2008). By
contrast, Bhat and Thirumangalakudi have reported a decrease
in IRS-1 levels in the brain of HFC-treated mice (Bhat and
Thirumangalakudi, 2013).
Interestingly, a recent study has demonstrated that HFD
potentiated Tau pathology in a mouse model of Tauopathy, in
a manner independent from insulin resistance, suggesting that
other factors, probably linked to obesity, might be implicated in
Tau pathology during T2DM (Leboucher et al., 2012).
Several investigators have also reported a deregulation in gene
and/or protein expression of the insulin-signaling pathway in
T3DM animal models. For example, the phosphorylation level of
PI3K was significantly decreased in mice treated with central STZ
(1.5mg/Kg, i.c.v.) (Deng et al., 2009). Moreover, Grunblatt et al.
have demonstrated that mRNA levels of both insulin and IRs are
decreased, whereas levels of phosphorylated IRβ are increased in
the hippocampi of T3DM rats (Grunblatt et al., 2007), (Table 1).
In summary, the involvement of the central insulin signal-
ing in Tau pathology is still controversial, with divergent results
showing a decrease, an increase, or even no significant changes
in the insulin signaling proteins in the brains of diabetic ani-
mals (Table 1). Therefore, further investigations are crucial to get
a more definitive picture of the role of central insulin signaling in
the progression of Tau pathology.
Implication of insulin signaling on Tau pathology
Beside its classical function of regulating glucose metabolism,
there is increasing evidence supporting a role for the
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FIGURE 1 | Insulin dysfunction might enhance Alzheimer’s disease
pathology through distinct mechanisms. Insulin dysfunction, manifested
by either T1DM, characterized by insulin deficiency; or T2DM, characterized
by insulin resistance, might lead to Tau phosphorylation and NFT formation,
one of the major histopathological hallmarks of Alzheimer’s disease. This
effect can be induced either directly, through kinases activation (such as
GSK-3β) and/or phosphatases inhibition (such as PP2A); or indirectly,
through the effect of hypothermia on kinases and phosphatases activities.
For note, insulin resistance might be related to Tau pathology through
several mechanisms, mainly including inflammation and stress.
Abbreviations: T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes
mellitus; GSK-3β: glycogen synthase kinase 3β; PP2A: protein phosphatase
2A; NFT: neurofibrillary tangles.
insulin-signaling pathway in neuronal development as well
as in learning and memory, therefore suggesting a crucial role
of insulin signaling in AD pathogenesis (Zhao and Alkon, 2001;
Craft and Watson, 2004; Gerozissis, 2008).
It has been proposed that insulin could affect Tau phospho-
rylation through the regulation of GSK-3β, since it is a kinase
downstream in the IR signaling pathway (Hong and Lee, 1997).
Although insulin administration in STZ treated mice completely
(Planel et al., 2007b), or partially (Clodfelder-Miller et al., 2006;
Jolivalt et al., 2008) rescued Tau phosphorylation in mice, these
findings are in contrast with human studies that report a higher
risk of AD in patients treated with insulin (Ott et al., 1999;
Luchsinger et al., 2001). However, one should be cautious in mak-
ing direct conclusions from these epidemiological studies, as it
might be because the patients were having a more severe stage
of diabetes that they required treatment with insulin. Thus, more
controlled studies in animals, as well as in human patients are
important to better understand the role of insulin in the brain.
Furthermore, several studies have investigated the impact of
rosiglitazone treatment on Tau phosphorylation in animal mod-
els. For example, Escribano et al. have observed a significant
decrease in Tau phosphorylation in the brain of transgenic hAPP
mice following rosiglitazone treatment (Escribano et al., 2010).
Similarly, Yoon et al. have demonstrated that this drug reduced
Tau phosphorylation both in vitro, and in the hippocampi of
OLETF T2DM rats. Interestingly, these authors suggest that this
effect might be due to a decrease in JNK activity (Yoon et al.,
2010).
Thus, although brain insulin signaling might have an impor-
tant effect on Tau phosphorylation, the molecular mechanisms
underlying this effect are far from clear. Better understanding of
these mechanisms might help to develop therapeutic strategies
aiming to reduce Tau hyperphosphorylation in the brain.
CONCLUSION
Overall, numerous preclinical studies examining the correlation
between insulin dysfunction and Tau hyperphosphorylation con-
verge to indicate that both T1DM and T2DM might affect Tau
pathology, either directly or indirectly (Figure 1). Apart from
some emerging evidences, mechanisms by which insulin dys-
function and/or other features of diabetes such as obesity and
inflammation contributes to Tau pathology are still not fully elu-
cidated. Therefore, further studies using other animal models
(e.g., ob/ob mice. . . ) are required to better understand the con-
tributions of these mechanisms to Tau hyperphosphorylation.
However, future studies must carefully report and control phys-
iological parameters such as body temperature, and should avoid
using anesthesia for the sacrifice of the animals.
In light of the increased incidence of diabetes in the young
population, future focus on the correlation between insulin dys-
function and Tau pathology may provide invaluable information
for the treatment and prevention of sporadic AD.
ACKNOWLEDGMENTS
This work was supported by a Biomedical Doctoral Award from
the Alzheimer Society of Canada (to Noura B. El Khoury), and
grants to Emmanuel Planel from the Canadian Institute of Health
Research (MOP-106423, PCN-102993), Fonds de Recherche en
Santé du Quebec (16205, 20048) and the Natural Sciences and
Engineering Research Council of Canada (354722). The funders
had no role in the decision to publish, or preparation of the
manuscript.
Noura B. El Khoury and Emmanuel Planel wrote the
manuscript. Marie-Amélie Papon, Maud Gratuze, and Alexis
Bretteville reviewed the manuscript.
REFERENCES
Alonso, A. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2001).
Hyperphosphorylation induces self-assembly of tau into tangles of paired heli-
cal filaments / straight filaments. Proc. Natl. Acad. Sci. U.S.A. 98, 6923–6928.
doi: 10.1073/pnas.121119298
Alonso, A. D., Grundke-Iqbal, I., Barra, H. S., and Iqbal, K. (1997). Abnormal
phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degen-
eration: sequestration of microtubule-associated proteins 1 and 2 and the
disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U.S.A.
94, 298–303. doi: 10.1073/pnas.94.1.298
Alonso, A. D. C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K.
(2004). Promotion of hyperphosphorylation by frontotemporal dementia tau
mutations. J. Biol. Chem. 279, 34873–34881. doi: 10.1074/jbc.M405131200
Andjelkovic, M., Jakubowicz, T., Cron, P., Ming, X. F., Han, J. W., and Hemmings,
B. A. (1996). Activation and phosphorylation of a pleckstrin homology domain
containing protein kinase (RAC-PK/PKB) promoted by serum and protein
phosphatase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 93, 5699–5704. doi:
10.1073/pnas.93.12.5699
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 11
El Khoury et al. Insulin and Tau
Arnaud, L., Robakis, N. K., and Figueiredo-Pereira, M. E. (2006). It may take
inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer’s
disease. Neurodegener. Dis. 3, 313–319. doi: 10.1159/000095638
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., and Hyman, B. T. (1992).
Neurofibrillary tangles but not senile plaques parallel duration and severity of
Alzheimer’s disease. Neurology 42, 631–639. doi: 10.1212/WNL.42.3.631
Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Li, Y., Arnold, S. E.,
Wang, Z., et al. (2006). Diabetes is related to cerebral infarction but
not to AD pathology in older persons. Neurology 67, 1960–1965. doi:
10.1212/01.wnl.0000247053.45483.4e
Augustinack, J., Schneider, A., Mandelkow, E.-M., and Hyman, B. T. (2002).
Specific tau phosphorylation sites correlate with severity of neuronal
cytopathology in Alzheimer’s disease. Acta Neuropathol. 103, 26–35. doi:
10.1007/s004010100423
Avila, J., Lucas, J. J., Perez, M., and Hernandez, F. (2004). Role of tau protein in
both physiological and pathological conditions. Physiol. Rev. 84, 361–384. doi:
10.1152/physrev.00024.2003
Banks,W. A., Jaspan, J. B., Huang,W., and Kastin, A. J. (1997a). Transport of insulin
across the blood-brain barrier: saturability at euglycemic doses of insulin.
Peptides 18, 1423–1429. doi: 10.1016/S0196-9781(97)00231-3
Banks, W. A., Jaspan, J. B., and Kastin, A. J. (1997b). Selective, physiologi-
cal transport of insulin across the blood-brain barrier: novel demonstra-
tion by species-specific radioimmunoassays. Peptides 18, 1257–1262. doi:
10.1016/S0196-9781(97)00198-8
Baskin, D. G., Figlewicz, D. P., Woods, S. C., Porte, D. Jr., and Dorsa, D.
M. (1987). Insulin in the brain. Annu. Rev. Physiol. 49, 335–347. doi:
10.1146/annurev.ph.49.030187.002003
Baskin, D. G., Wilcox, B. J., Figlewicz, D. P., and Dorsa, D. M. (1988). Insulin
and insulin-like growth factors in the CNS. Trends Neurosci. 11, 107–111. doi:
10.1016/0166-2236(88)90155-5
Becker, K., Freude, S., Zemva, J., Stohr, O., Krone, W., and Schubert,
M. (2012). Chronic peripheral hyperinsulinemia has no substantial influ-
ence on tau phosphorylation in vivo. Neurosci. Lett. 516, 306–310. doi:
10.1016/j.neulet.2012.04.022
Benedict, C., Brooks, S. J., Kullberg, J., Burgos, J., Kempton, M. J., Nordenskjold,
R., et al. (2012). Impaired insulin sensitivity as indexed by the HOMA score is
associated with deficits in verbal fluency and temporal lobe gray matter volume
in the elderly. Diabetes Care 35, 488–494. doi: 10.2337/dc11-2075
Bhaskar, K., Konerth, M., Kokiko-Cochran, O. N., Cardona, A., Ransohoff, R.
M., and Lamb, B. T. (2010). Regulation of tau pathology by the microglial
fractalkine receptor. Neuron 68, 19–31. doi: 10.1016/j.neuron.2010.08.023
Bhat, N. R., and Thirumangalakudi, L. (2013). Increased Tau phosphoryla-
tion and impaired brain insulin/IGF signaling in mice fed a high fat/high
cholesterol diet. J. Alzheimers Dis. 36, 781–789. doi: 10.3233/JAD-2012-
121030
Bierer, L. M., Hof, P. R., Purohit, D. P., Carlin, L., Schmeidler, J., Davis, K.
L., et al. (1995). Neocortical neurofibrillary tangles correlate with dementia
severity in Alzheimer’s disease. Arch. Neurol. 52, 81–88. doi: 10.1001/arch-
neur.1995.00540250089017
Biernat, J., Gustke, N., Drewes, G., Mandelkow, E. M., and Mandelkow, E. (1993).
Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: dis-
tinction between PHF-like immunoreactivity and microtubule binding.Neuron
11, 153–163. doi: 10.1016/0896-6273(93)90279-Z
Braak, E., Griffing, K., Arai, K., Bohl, J., Bratzke, H., and Braak, H. (1999).
Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur.
Arch. Psychiatry Clin. Neurosci. 249(Suppl. 3), 14–22. doi: 10.1007/PL00014168
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/BF00308809
Braak, H., and Braak, E. (1997). Frequency of stages of Alzheimer-related lesions
in different age categories. Neurobiol. Aging 18, 351–357. doi: 10.1016/S0197-
4580(97)00056-0
Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee,
V. M. (1993). Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease
recapitulates development and contributes to reduced microtubule binding.
Neuron 10, 1089–1099. doi: 10.1016/0896-6273(93)90057-X
Brant, A. M., Jess, T. J., Milligan, G., Brown, C. M., and Gould, G. W. (1993).
Immunological analysis of glucose transporters expressed in different regions
of the rat brain and central nervous system. Biochem. Biophys. Res. Commun.
192, 1297–1302. doi: 10.1006/bbrc.1993.1557
Brazil, D. P., and Hemmings, B. A. (2001). Ten years of protein kinase B signalling:
a hard Akt to follow. Trends Biochem. Sci. 26, 657–664. doi: 10.1016/S0968-
0004(01)01958-2
Bretteville, A., and Planel, E. (2008). Tau aggregates: toxic, inert, or protective
species? J. Alzheimers. Dis. 14, 431–436.
Brion, J. P., Passareiro, H., Nunez, J., and Flament-Durand, J. (1985). Mise en
évidence immunologique de la protéine tau au niveau des lésions de dégénéres-
cence neurofibrillaire de la maladie d’Alzheimer. Arch. Biol. (Bruxelles) 95,
229–235.
Bruning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C.,
et al. (2000). Role of brain insulin receptor in control of body weight and
reproduction. Science 289, 2122–2125. doi: 10.1126/science.289.5487.2122
Bruning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Horsch, D., Accili, D.,
et al. (1998). A muscle-specific insulin receptor knockout exhibits features of
the metabolic syndrome of NIDDM without altering glucose tolerance. Mol.
Cell 2, 559–569. doi: 10.1016/S1097-2765(00)80155-0
Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., and Hof, P. R. (2000).
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.
Brain Res. Brain Res. Rev. 33, 95–130. doi: 10.1016/S0165-0173(00)00019-9
Burnouf, S., Martire, A., Derisbourg, M., Laurent, C., Belarbi, K., Leboucher,
A., et al. (2013). NMDA receptor dysfunction contributes to impaired brain-
derived neurotrophic factor-induced facilitation of hippocampal synaptic trans-
mission in a Tau transgenic model.Aging Cell 12, 11–23. doi: 10.1111/acel.12018
Bussière, T., Hof, P. R., Mailliot, C., Brown, C. D., Caillet-Boudin, M. L., Perl, D. P.,
et al. (1999). Phosphorylated serine422 on tau proteins is a pathological epitope
found in several diseases with neurofibrillary degeneration. Acta Neuropathol.
(Berl.) 97, 221–230. doi: 10.1007/s004010050978
Butner, K. A., and Kirschner, M. W. (1991). Tau protein binds to microtubules
through a flexible array of distributed weak sites. J. Cell Biol. 115, 717–730. doi:
10.1083/jcb.115.3.717
CDC. (2008). National Diabetes Fact Sheet: General Information and National
Estimates on Diabetes in the United States, 2007. Atlanta, GA: U.S. Department
of Health and Human Services, Centers for Disease Control and Prevention.
Chen, J., Kanai, Y., Cowan, N. J., and Hirokawa, N. (1992). Projection domains
of MAP2 and tau determine spacings between microtubules in dendrites and
axons. Nature 360, 674–677. doi: 10.1038/360674a0
Chen, S., Liu, A. R., An, F. M., Yao, W. B., and Gao, X. D. (2011).
Amelioration of neurodegenerative changes in cellular and rat models of
diabetes-related Alzheimer’s disease by exendin-4. Age (Dordr). 34, 1211–1224.
doi: 10.1007/s11357-011-9303-8
Chen, Y., Liang, Z., Blanchard, J., Dai, C. L., Sun, S., Lee, M. H., et al. (2013a).
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: sim-
ilarities to and differences from the transgenic model (3xTg-AD mouse). Mol.
Neurobiol. 47, 711–725. doi: 10.1007/s12035-012-8375-5
Chen, Y., Liang, Z., Tian, Z., Blanchard, J., Dai, C. L., Chalbot, S., et al.
(2013b). Intracerebroventricular Streptozotocin Exacerbates Alzheimer-Like
Changes of 3xTg-AD Mice. Mol. Neurobiol. doi: 10.1007/s12035-013-
8539-y. [Epub ahead of print].
Chu, W. Z., and Qian, C. Y. (2005). Expressions of Abeta1-40, Abeta1-42, tau202,
tau396 and tau404 after intracerebroventricular injection of streptozotocin in
rats. Di Yi Jun. Yi Da Xue Xue Bao 25, 168–170, 173.
Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977a). Physical and chemical
properties of purified tau factor and the role of tau in microtubule assembly.
J. Mol. Biol. 116, 227–247. doi: 10.1016/0022-2836(77)90214-5
Cleveland, D. W., Hwo, S. Y., and Kirschner, M. W. (1977b). Purification of tau,
a microtubule-associated protein that induces assembly of microtubules from
purified tubulin. J. Mol. Biol. 116, 207–225. doi: 10.1016/0022-2836(77)90213-3
Clodfelder-Miller, B., De Sarno, P., Zmijewska, A. A., Song, L., and Jope, R.
S. (2005). Physiological and pathological changes in glucose regulate brain
Akt and glycogen synthase kinase-3. J. Biol. Chem. 280, 39723–39731. doi:
10.1074/jbc.M508824200
Clodfelder-Miller, B. J., Zmijewska, A. A., Johnson, G. V., and Jope, R. S.
(2006). Tau is hyperphosphorylated at multiple sites in mouse brain in vivo
after streptozotocin-induced insulin deficiency. Diabetes 55, 3320–3325. doi:
10.2337/db06-0485
Coleman, D. L. (1978). Obese and diabetes: two mutant genes causing diabetes-
obesity syndromes in mice. Diabetologia 14, 141–148. doi: 10.1007/BF00429772
Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A.,
et al. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 12
El Khoury et al. Insulin and Tau
mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 29–38. doi:
10.1001/archneurol.2011.233
Craft, S., and Watson, G. S. (2004). Insulin and neurodegenerative disease: shared
and specific mechanisms. Lancet Neurol. 3, 169–178. doi: 10.1016/S1474-
4422(04)00681-7
Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., et al.
(2013a). Glucose levels and risk of dementia.N. Engl. J. Med. 369, 540–548. doi:
10.1056/NEJMoa1215740
Crane, P. K., Walker, R., and Larson, E. B. (2013b). Glucose levels and risk of
dementia. N. Engl. J. Med. 369, 1863–1864. doi: 10.1056/NEJMoa1215740
Cryer, P. E. (1997). Hypoglycemia: Pathophysiology, Diagnosis, and Treatment. New
York, NY: Oxford University Press.
Cryer, P. E. (2001). Hypoglycemia risk reduction in type 1 diabetes. Exp. Clin.
Endocrinol. Diabetes 109(Suppl. 2), S412–S423. doi: 10.1055/s-2001-18599
Cryer, P. E. (2004). Diverse causes of hypoglycemia-associated autonomic failure in
diabetes. N. Engl. J. Med. 350, 2272–2279. doi: 10.1056/NEJMra031354
Cryer, P. E., Davis, S. N., and Shamoon, H. (2003). Hypoglycemia in diabetes.
Diabetes Care 26, 1902–1912. doi: 10.2337/diacare.26.6.1902
Dahlquist, G., and Kallen, B. (2007). School performance in children with type
1 diabetes–a population-based register study. Diabetologia 50, 957–964. doi:
10.1007/s00125-007-0615-2
Dandona, P. (2002). Endothelium, inflammation, and diabetes. Curr. Diab. Rep. 2,
311–315. doi: 10.1007/s11892-002-0019-0
De Felice, F. G. (2013). Alzheimer’s disease and insulin resistance: translating
basic science into clinical applications. J. Clin. Invest. 123, 531–539. doi:
10.1172/JCI64595
Defronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. Med. Clin. North
Am. 88, 787–835. doi: 10.1016/j.mcna.2004.04.013
Delacourte, A., and Buée, L. (2000). Tau pathology: a marker of neurodegenerative
disorders. Curr. Opin. Neurol. 13, 371–376. doi: 10.1097/00019052-200008000-
00002
Delacourte, A., David, J. P., Sergeant, N., Buée, L., Wattez, A., Vermersch, P., et al.
(1999). The biochemical pathway of neurofibrillary degeneration in aging and
Alzheimer’s disease. Neurology 52, 1158–1165. doi: 10.1212/WNL.52.6.1158
Delacourte, A., Sergeant, N., Wattez, A., Maurage, C. A., Lebert, F., Pasquier,
F., et al. (2002). Tau aggregation in the hippocampal formation: an ageing
or a pathological process? Exp. Gerontol. 37, 1291–1296. doi: 10.1016/S0531-
5565(02)00141-9
Delaere, P., Duyckaerts, C., Brion, J. P., Poulain, V., and Hauw, J. J. (1989).
Tau, paired helical filaments and amyloid in the neocortex: a morphome-
tric study of 15 cases with graded intellectual status in aging and senile
dementia of Alzheimer type. Acta Neuropathol. (Berl.) 77, 645–653. doi:
10.1007/BF00687893
De La Monte, S. M., Longato, L., Tong, M., and Wands, J. R. (2009). Insulin resis-
tance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and
non-alcoholic steatohepatitis. Curr. Opin. Investig. Drugs 10, 1049–1060.
De La Monte, S. M., Tong, M., Lester-Coll, N., Plater, M. Jr., and Wands, J.
R. (2006). Therapeutic rescue of neurodegeneration in experimental type 3
diabetes: relevance to Alzheimer’s disease. J. Alzheimers. Dis. 10, 89–109.
Delaney, C. A., Dunger, A., Di Matteo, M., Cunningham, J. M., Green, M. H., and
Green, I. C. (1995). Comparison of inhibition of glucose-stimulated insulin
secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl
nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-
releasing or O6-alkylating ability. Biochem. Pharmacol. 50, 2015–2020. doi:
10.1016/0006-2952(95)02102-7
Deng, Y., Li, B., Liu, Y., Iqbal, K., Grundke-Iqbal, I., and Gong, C.
X. (2009). Dysregulation of insulin signaling, glucose transporters, O-
GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain:
Implication for Alzheimer’s disease. Am. J. Pathol. 175, 2089–2098. doi:
10.2353/ajpath.2009.090157
Deters, N., Ittner, L. M., and Gotz, J. (2009). Substrate-specific reduction of
PP2A activity exaggerates tau pathology. Biochem. Biophys. Res. Commun. 379,
400–405. doi: 10.1016/j.bbrc.2008.12.140
Devaskar, S. U., Giddings, S. J., Rajakumar, P. A., Carnaghi, L. R., Menon, R. K., and
Zahm, D. S. (1994). Insulin gene expression and insulin synthesis inmammalian
neuronal cells. J. Biol. Chem. 269, 8445–8454.
Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H.
E., et al. (1995).Microtubule-associated protein/microtubule affinity-regulating
kinase (p110mark). A novel protein kinase that regulates tau-microtubule inter-
actions and dynamic instability by phosphorylation at the Alzheimer-specific
site serine 262. J. Biol. Chem. 270, 7679–7688.
Du, L. L., Xie, J. Z., Cheng, X. S., Li, X. H., Kong, F. L., Jiang, X., et al.
(2013). Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-
induced tau hyperphosphorylation and cognitive injuries in rat hippocampi.
Age (Dordr). doi: 10.1007/s11357-013-9592-1. [Epub ahead of print].
Duarte, A. I., Moreira, P. I., and Oliveira, C. R. (2012). Insulin in central nervous
system: more than just a peripheral hormone. J. Aging Res. 2012:384017. doi:
10.1155/2012/384017
Duelli, R., Schrock, H., Kuschinsky, W., and Hoyer, S. (1994).
Intracerebroventricular injection of streptozotocin induces discrete local
changes in cerebral glucose utilization in rats. Int. J. Dev. Neurosci. 12, 737–743.
doi: 10.1016/0736-5748(94)90053-1
Duvillie, B., Cordonnier, N., Deltour, L., Dandoy-Dron, F., Itier, J. M., Monthioux,
E., et al. (1997). Phenotypic alterations in insulin-deficient mutant mice. Proc.
Natl. Acad. Sci. U.S.A. 94, 5137–5140. doi: 10.1073/pnas.94.10.5137
Duyckaerts, C., Bennecib, M., Grignon, Y., Uchihara, T., He, Y., Piette, F., et al.
(1997). Modeling the relation between neurofibrillary tangles and intellectual
status. Neurobiol. Aging 18, 267–273. doi: 10.1016/S0197-4580(97)80306-5
Duyckaerts, C., Colle, M. A., Dessi, F., Piette, F., and Hauw, J. J. (1998). Progression
of Alzheimer histopathological changes. Acta Neurol. Belg. 98, 180–185.
Ellis, E. A., Grant, M. B., Murray, F. T., Wachowski, M. B., Guberski, D. L.,
Kubilis, P. S., et al. (1998). Increased NADH oxidase activity in the retina of the
BBZ/Wor diabetic rat. Free Radic. Biol. Med. 24, 111–120. doi: 10.1016/S0891-
5849(97)00202-5
Escribano, L., Simon, A. M., Gimeno, E., Cuadrado-Tejedor, M., Lopez De
Maturana, R., Garcia-Osta, A., et al. (2010). Rosiglitazone rescues memory
impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced
amyloid and tau pathology. Neuropsychopharmacology 35, 1593–1604. doi:
10.1038/npp.2010.32
Festa, A., Williams, K., D’agostino, R. Jr., Wagenknecht, L. E., and Haffner, S.
M. (2006). The natural course of beta-cell function in nondiabetic and dia-
betic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55,
1114–1120. doi: 10.2337/diabetes.55.04.06.db05-1100
Fox, M. A., Chen, R. S., and Holmes, C. S. (2003). Gender differences in
memory and learning in children with insulin-dependent diabetes mellitus
(IDDM) over a 4-year follow-up interval. J. Pediatr. Psychol. 28, 569–578. doi:
10.1093/jpepsy/jsg047
Freiherr, J., Hallschmid, M., Frey, W. H., 2nd, Brunner, Y. F., Chapman, C. D.,
Holscher, C., et al. (2013). Intranasal insulin as a treatment for Alzheimer’s dis-
ease: a review of basic research and clinical evidence. CNS Drugs 27, 505–514.
doi: 10.1007/s40263-013-0076-8
Frolich, L., Blum-Degen, D., Riederer, P., and Hoyer, S. (1999). A disturbance in the
neuronal insulin receptor signal transduction in sporadic Alzheimer’s disease.
Ann. N. Y. Acad. Sci. 893, 290–293. doi: 10.1111/j.1749-6632.1999.tb07839.x
Ganda, O. P., Rossini, A. A., and Like, A. A. (1976). Studies on streptozotocin
diabetes. Diabetes 25, 595–603. doi: 10.2337/diab.25.7.595
Gasparini, L., Netzer, W. J., Greengard, P., and Xu, H. (2002). Does insulin dysfunc-
tion play a role in Alzheimer’s disease? Trends Pharmacol. Sci. 23, 288–293. doi:
10.1016/S0165-6147(02)02037-0
Gerozissis, K. (2008). Brain insulin, energy and glucose homeostasis; genes,
environment and metabolic pathologies. Eur. J. Pharmacol. 585, 38–49. doi:
10.1016/j.ejphar.2008.01.050
Giannakopoulos, P., Herrmann, F. R., Bussiere, T., Bouras, C., Kovari, E., Perl,
D. P., et al. (2003). Tangle and neuron numbers, but not amyloid load, pre-
dict cognitive status in Alzheimer’s disease. Neurology 60, 1495–1500. doi:
10.1212/01.WNL.0000063311.58879.01
Glenner, G. G., and Wong, C. W. (1984). Alzheimer’s disease: initial report
of the purification and characterization of a novel cerebrovascular amyloid
protein. Biochem. Biophys. Res. Commun. 120, 885–890. doi: 10.1016/S0006-
291X(84)80190-4
Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren,
M., et al. (1994). Epitope mapping of monoclonal antibodies to the paired heli-
cal filaments of Alzheimer’s disease: identification of phosphorylation sites in
tau protein. Biochem. J. 301, 871–877.
Goedert, M., Jakes, R., Crowther, R. A., Six, J., Lubke, U., Vandermeeren, M., et al.
(1993). The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 13
El Khoury et al. Insulin and Tau
disease recapitulates phosphorylation during development. Proc. Natl. Acad. Sci.
U.S.A 90, 5066–5070. doi: 10.1073/pnas.90.11.5066
Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., and Crowther, R. A. (1989).
Cloning and sequencing of the cDNA encoding an isoform of microtubule-
associated protein tau containing four tandem repeats: differential expression
of tau protein mRNAs in human brain. EMBO J. 8, 393–399.
Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R.
C., et al. (1997). Neuronal loss correlates with but exceeds neurofibrillary
tangles in Alzheimer’s disease. Ann. Neurol. 41, 17–24. doi: 10.1002/ana.
410410106
Gong, C. X., Grundke-Iqbal, I., and Iqbal, K. (1994). Dephosphorylation of
Alzheimer’s disease abnormally phosphorylated tau by protein phosphatase-2A.
Neuroscience 61, 765–772. doi: 10.1016/0306-4522(94)90400-6
Gong, C. X., and Iqbal, K. (2008). Hyperphosphorylation of microtubule-
associated protein tau: a promising therapeutic target for Alzheimer disease.
Curr. Med. Chem. 15, 2321–2328. doi: 10.2174/092986708785909111
Gong, C. X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., and Iqbal, K.
(2000). Phosphorylation of microtubule-associated protein tau is regulated by
protein phosphatase 2A in mammalian brain. Implications for neurofibril-
lary degeneration in Alzheimer’s disease. J. Biol. Chem. 275, 5535–5544. doi:
10.1074/jbc.275.8.5535
Gong, C. X., Shaikh, S., Wang, J. Z., Zaidi, T., Grundke-Iqbal, I., and Iqbal, K.
(1995). Phosphatase activity toward abnormally phosphorylated tau: decrease
in Alzheimer disease brain. J. Neurochem. 65, 732–738. doi: 10.1046/j.1471-
4159.1995.65020732.x
Gong, C. X., Singh, T. J., Grundke-Iqbal, I., and Iqbal, K. (1993). Phosphoprotein
phosphatase activities in Alzheimer disease brain. J. Neurochem. 61, 921–927.
doi: 10.1111/j.1471-4159.1993.tb03603.x
Goodner, C. J., and Berrie, M. A. (1977). The failure of rat hypothalamic tissues to
take up labeled insulin in vivo or to respond to insulin in vitro. Endocrinology
101, 605–612. doi: 10.1210/endo-101-2-605
Gotz, J., Chen, F., Barmettler, R., and Nitsch, R. M. (2001). Tau filament forma-
tion in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529–534. doi:
10.1074/jbc.M006531200
Grunblatt, E., Salkovic-Petrisic, M., Osmanovic, J., Riederer, P., and Hoyer,
S. (2007). Brain insulin system dysfunction in streptozotocin intrac-
erebroventricularly treated rats generates hyperphosphorylated tau
protein. J. Neurochem. 101, 757–770. doi: 10.1111/j.1471-4159.2006.
04368.x
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., andWisniewski,
H. M. (1986). Microtubule-associated protein tau. A component of Alzheimer
paired helical filaments. J. Biol. Chem. 261, 6084–6089.
Guillozet, A. L., Weintraub, S., Mash, D. C., and Mesulam, M. M. (2003).
Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive
impairment. Arch. Neurol. 60, 729–736. doi: 10.1001/archneur.60.5.729
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (1994).
Domains of tau protein and interactions with microtubules. Biochemistry 33,
9511–9522. doi: 10.1021/bi00198a017
Hak, A. E., Pols, H. A., Stehouwer, C. D., Meijer, J., Kiliaan, A. J., Hofman, A.,
et al. (2001). Markers of inflammation and cellular adhesion molecules in rela-
tion to insulin resistance in nondiabetic elderly: the Rotterdam study. J. Clin.
Endocrinol. Metab. 86, 4398–4405. doi: 10.1210/jc.86.9.4398
Han, W. N., Holscher, C., Yuan, L., Yang, W., Wang, X. H., Wu, M. N., et al.
(2013). Liraglutide protects against amyloid-beta protein-induced impairment
of spatial learning and memory in rats. Neurobiol. Aging 34, 576–588. doi:
10.1016/j.neurobiolaging.2012.04.009
Hardy, J. A., and Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256, 184–185. doi: 10.1126/science.1566067
Harman, D. (2002). Alzheimer’s disease: role of aging in pathogenesis. Ann.
N.Y. Acad. Sci. 959, 384–395; discussion 463–385. doi: 10.1111/j.1749-
6632.2002.tb02109.x
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K.,
et al. (1998). Role for neuronally derived fractalkine in mediating interac-
tions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci.
U.S.A. 95, 10896–10901. doi: 10.1073/pnas.95.18.10896
Hasegawa, M., Jakes, R., Crowther, R. A., Lee, V. M., Ihara, Y., and Goedert, M.
(1996). Characterization of mAb AP422, a novel phosphorylation-dependent
monoclonal antibody against tau protein. FEBS Lett. 384, 25–30. doi:
10.1016/0014-5793(96)00271-2
Havrankova, J., Roth, J., and Brownstein, M. (1978a). Insulin receptors are widely
distributed in the central nervous system of the rat. Nature 272, 827–829. doi:
10.1038/272827a0
Havrankova, J., Schmechel, D., Roth, J., and Brownstein, M. (1978b). Identification
of insulin in rat brain. Proc. Natl. Acad. Sci. U.S.A. 75, 5737–5741. doi:
10.1073/pnas.75.11.5737
Heidenreich, K. A., and Gilmore, P. R. (1985). Structural and functional char-
acteristics of insulin receptors in rat neuroblastoma cells. J. Neurochem. 45,
1642–1648. doi: 10.1111/j.1471-4159.1985.tb07237.x
Heidenreich, K. A., Zahniser, N. R., Berhanu, P., Brandenburg, D., and Olefsky,
J. M. (1983). Structural differences between insulin receptors in the brain and
peripheral target tissues. J. Biol. Chem. 258, 8527–8530.
Hernandez, F., Lucas, J. J., and Avila, J. (2013). GSK3 and tau: two convergence
points in Alzheimer’s disease. J. Alzheimers. Dis. 33(Suppl. 1), S141–S144. doi:
10.3233/JAD-2012-129025
Himmler, A., Drechsel, D., Kirschner, M.W., andMartin, D.W. Jr. (1989). Tau con-
sists of a set of proteins with repeated C-terminal microtubule- binding domains
and variable N-terminal domains. Mol. Cell. Biol. 9, 1381–1388.
Hong, M., and Lee, V. M. (1997). Insulin and insulin-like growth factor-1 reg-
ulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272,
19547–19553. doi: 10.1074/jbc.272.31.19547
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M.
K., et al. (2010). Tau mislocalization to dendritic spines mediates synaptic
dysfunction independently of neurodegeneration. Neuron 68, 1067–1081. doi:
10.1016/j.neuron.2010.11.030
Hoyer, S. (1998). Is sporadic Alzheimer disease the brain type of non-insulin
dependent diabetes mellitus? A challenging hypothesis. J. Neural. Transm. 105,
415–422. doi: 10.1007/s007020050067
Hu, S. H., Jiang, T., Yang, S. S., and Yang, Y. (2013). Pioglitazone ameliorates intrac-
erebral insulin resistance and tau-protein hyperphosphorylation in rats with
type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 121, 220–224. doi: 10.1055/s-
0032-1333277
Hummel, K. P., Dickie, M. M., and Coleman, D. L. (1966). Diabetes, a new muta-
tion in the mouse. Science 153, 1127–1128. doi: 10.1126/science.153.3740.1127
IDF. (2013). IDF Diabetes Atlas, 6th Edn. Brussels: International Diabetes
Federation.
Ishrat, T., Khan, M. B., Hoda, M. N., Yousuf, S., Ahmad, M., Ansari, M. A.,
et al. (2006). Coenzyme Q10 modulates cognitive impairment against intrac-
erebroventricular injection of streptozotocin in rats. Behav. Brain Res. 171, 9–16.
doi: 10.1016/j.bbr.2006.03.009
Jolivalt, C. G., Hurford, R., Lee, C. A., Dumaop,W., Rockenstein, E., andMasliah, E.
(2010). Type 1 diabetes exaggerates features of Alzheimer’s disease in APP trans-
genic mice. Exp. Neurol. 223, 422–431. doi: 10.1016/j.expneurol.2009.11.005
Jolivalt, C. G., Lee, C. A., Beiswenger, K. K., Smith, J. L., Orlov, M., Torrance,
M. A., et al. (2008). Defective insulin signaling pathway and increased glyco-
gen synthase kinase-3 activity in the brain of diabetic mice: parallels with
Alzheimer’s disease and correction by insulin. J. Neurosci. Res. 86, 3265–3274.
doi: 10.1002/jnr.21787
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien,
P., et al. (2010). High-fat diet aggravates amyloid-beta and tau patholo-
gies in the 3xTg-AD mouse model. Neurobiol. Aging 31, 1516–1531. doi:
10.1016/j.neurobiolaging.2008.08.022
Jung, H. J., Kim, Y. J., Eggert, S., Chung, K. C., Choi, K. S., and Park, S. A. (2013).
Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic
rats correlate with a reduced expression of p62. Exp. Neurol. 248, 441–450. doi:
10.1016/j.expneurol.2013.07.013
Jung, H. J., Park, S. S., Mok, J. O., Lee, T. K., Park, C. S., and Park, S. A. (2011).
Increased expression of three-repeat isoforms of tau contributes to tau pathol-
ogy in a rat model of chronic type 2 diabetes. Exp. Neurol. 228, 232–241. doi:
10.1016/j.expneurol.2011.01.012
Ke, Y. D., Delerue, F., Gladbach, A., Gotz, J., and Ittner, L. M. (2009). Experimental
diabetes mellitus exacerbates tau pathology in a transgenic mouse model of
Alzheimer’s disease. PLoS ONE 4:e7917. doi: 10.1371/journal.pone.0007917
Kilgour, R. D., and Williams, P. A. (1996). Effects of diabetes and food deprivation
on shivering activity during progressive hypothermia in the rat. Comp. Biochem.
Physiol. A Physiol. 114, 159–165. doi: 10.1016/0300-9629(95)02108-6
Kilgour, R. D., andWilliams, P. A. (1998). Diabetes affects blood pressure and heart
rate responses during acute hypothermia. Acta Physiol. Scand. 162, 27–32. doi:
10.1046/j.1365-201X.1998.0283f.x
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 14
El Khoury et al. Insulin and Tau
Kim, B., Backus, C., Oh, S., Hayes, J. M., and Feldman, E. L. (2009). Increased tau
phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.
Endocrinology 150, 5294–5301. doi: 10.1210/en.2009-0695
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., and Laferla,
F. M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau
pathology by a cyclin-dependent kinase 5-mediated pathway in a trans-
genic model of Alzheimer’s disease. J. Neurosci. 25, 8843–8853. doi:
10.1523/JNEUROSCI.2868-05.2005
Krogh-Madsen, R., Plomgaard, P., Keller, P., Keller, C., and Pedersen, B. K. (2004).
Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expres-
sion in human subcutaneous adipose tissue. Am. J. Physiol. Endocrinol. Metab.
286, E234–E238. doi: 10.1152/ajpendo.00274.2003
Ksiezak-Reding, H., Pyo, H. K., Feinstein, B., and Pasinetti, G. M. (2003). Akt/PKB
kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro.
Biochim. Biophys. Acta 1639, 159–168. doi: 10.1016/j.bbadis.2003.09.001
Kulkarni, R. N., Bruning, J. C., Winnay, J. N., Postic, C., Magnuson, M. A., and
Kahn, C. R. (1999). Tissue-specific knockout of the insulin receptor in pancre-
atic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.
Cell 96, 329–339. doi: 10.1016/S0092-8674(00)80546-2
Labouèbe, G., Liu, S., Dias, C., Zou, H., Wong, J. C., Karunakaran, S., et al. (2013).
Insulin induces long-term depression of ventral tegmental area dopamine neu-
rons via endocannabinoids. Nat. Neurosci. 16, 300–308. doi: 10.1038/nn.3321
Laferla, F. M., Green, K. N., and Oddo, S. (2007). Intracellular amyloid-beta in
Alzheimer’s disease. Nat. Rev. Neurosci. 8, 499–509. doi: 10.1038/nrn2168
Lamberts, S. W., Van Den Beld, A. W., and Van Der Lely, A. J. (1997).
The endocrinology of aging. Science 278, 419–424. doi: 10.1126/sci-
ence.278.5337.419
Lannert, H., and Hoyer, S. (1998). Intracerebroventricular administration of strep-
tozotocin causes long-term diminutions in learning and memory abilities and
in cerebral energy metabolism in adult rats. Behav. Neurosci. 112, 1199–1208.
doi: 10.1037/0735-7044.112.5.1199
Leboucher, A., Laurent, C., Fernandez-Gomez, F. J., Burnouf, S., Troquier, L.,
Eddarkaoui, S., et al. (2012). Detrimental effects of diet-induced obesity on tau
pathology is independent of insulin resistance in tau transgenic mice. Diabetes
65, 1681–1688. doi: 10.2337/db12-0866
Le Freche, H., Brouillette, J., Fernandez-Gomez, F. J., Patin, P., Caillierez, R.,
Zommer, N., et al. (2012). Tau phosphorylation and sevoflurane anesthesia: an
association to postoperative cognitive impairment.Anesthesiology 116, 779–787.
doi: 10.1097/ALN.0b013e31824be8c7
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O’brien,
P. C., et al. (1997). Risk of dementia among persons with diabetes melli-
tus: a population-based cohort study. Am. J. Epidemiol. 145, 301–308. doi:
10.1093/oxfordjournals.aje.a009106
Leiter, E. H. (2001). The NOD mouse: a model for insulin-dependent
diabetes mellitus. Curr Protoc Immunol. Chapter 15, Unit 15.9. doi:
10.1002/0471142735.im1509s24
Leloup, C., Arluison, M., Lepetit, N., Cartier, N., Marfaing-Jallat, P., Ferre, P., et al.
(1994). Glucose transporter 2 (GLUT 2): expression in specific brain nuclei.
Brain Res. 638, 221–226. doi: 10.1016/0006-8993(94)90653-X
Le Roith, D., and Zick, Y. (2001). Recent advances in our understanding
of insulin action and insulin resistance. Diabetes Care 24, 588–597. doi:
10.2337/diacare.24.3.588
Lerorrtt, D., Rojeski, M., and Roth, J. (1988). Insulin receptors in brain and
other tissues: similarities and differences. Neurochem. Int. 12, 419–423. doi:
10.1016/0197-0186(88)90023-X
Lesort, M., and Johnson, G. V. (2000). Insulin-like growth factor-1 and insulin
mediate transient site- selective increases in tau phosphorylation in pri-
mary cortical neurons. Neuroscience 99, 305–316. doi: 10.1016/S0306-4522(00)
00200-1
Lesort, M., Jope, R. S., and Johnson, G. V. (1999). Insulin transiently
increases tau phosphorylation: involvement of glycogen synthase kinase-3beta
and Fyn tyrosine kinase. J. Neurochem. 72, 576–584. doi: 10.1046/j.1471-
4159.1999.0720576.x
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., and De LaMonte,
S. M. (2006). Intracerebral streptozotocin model of type 3 diabetes: relevance to
sporadic Alzheimer’s disease. J. Alzheimers. Dis. 9, 13–33.
Lewis, J., Dickson, D.W., Lin,W. L., Chisholm, L., Corral, A., Jones, G., et al. (2001).
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant
tau and APP. Science 293, 1487–1491. doi: 10.1126/science.1058189
Li, J., Deng, J., Sheng, W., and Zuo, Z. (2012a). Metformin attenuates Alzheimer’s
disease-like neuropathology in obese, leptin-resistant mice. Pharmacol.
Biochem. Behav. 101, 564–574. doi: 10.1016/j.pbb.2012.03.002
Li, L., Zhang, Z. F., Holscher, C., Gao, C., Jiang, Y. H., and Liu, Y. Z.
(2012b). (Val(8)) glucagon-like peptide-1 prevents tau hyperphosphoryla-
tion, impairment of spatial learning and ultra-structural cellular damage
induced by streptozotocin in rat brains. Eur. J. Pharmacol. 674, 280–286. doi:
10.1016/j.ejphar.2011.11.005
Li, Y., Liu, L., Barger, S. W., and Griffin, W. S. (2003). Interleukin-1 mediates
pathological effects of microglia on tau phosphorylation and on synaptophysin
synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 23,
1605–1611.
Li, Z. G., Zhang, W., and Sima, A. A. (2007). Alzheimer-like changes in rat models
of spontaneous diabetes. Diabetes 56, 1817–1824. doi: 10.2337/db07-0171
Lien, E., Means, T. K., Heine, H., Yoshimura, A., Kusumoto, S., Fukase, K., et al.
(2000). Toll-like receptor 4 imparts ligand-specific recognition of bacterial
lipopolysaccharide. J. Clin. Invest. 105, 497–504. doi: 10.1172/JCI8541
Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2005). Contributions of pro-
tein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phospho-
rylation. Eur. J. Neurosci. 22, 1942–1950. doi: 10.1111/j.1460-9568.2005.04391.x
Luchsinger, J. A., Tang, M. X., Shea, S., and Mayeux, R. (2004).
Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187–1192. doi:
10.1212/01.WNL.0000140292.04932.87
Luchsinger, J. A., Tang, M. X., Stern, Y., Shea, S., and Mayeux, R. (2001). Diabetes
mellitus and risk of Alzheimer’s disease and dementia with stroke in a multieth-
nic cohort. Am. J. Epidemiol. 154, 635–641. doi: 10.1093/aje/154.7.635
Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al.
(1999). Soluble amyloid beta peptide concentration as a predictor of synaptic
change in Alzheimer’s disease. Am. J. Pathol. 155, 853–862. doi: 10.1016/S0002-
9440(10)65184-X
Makino, S., Kunimoto, K., Muraoka, Y., Mizushima, Y., Katagiri, K., and Tochino,
Y. (1980). Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu
29, 1–13.
Marks, J. L., and Eastman, C. J. (1990). Ontogeny of insulin binding in different
regions of the rat brain. Dev. Neurosci. 12, 349–358. doi: 10.1159/000111863
Marks, J. L., King, M. G., and Baskin, D. G. (1991). Localization of insulin and
type 1 IGF receptors in rat brain by in vitro autoradiography and in situ
hybridization. Adv. Exp. Med. Biol. 293, 459–470. doi: 10.1007/978-1-4684-
5949-4_41
Matsuo, E. S., Shin, R. W., Billingsley, M. L., Van Devoorde, A., O’connor,
M., Trojanowski, J. Q., et al. (1994). Biopsy-derived adult human brain
tau is phosphorylated at many of the same sites as Alzheimer’s disease
paired helical filament tau. Neuron 13, 989–1002. doi: 10.1016/0896-6273(94)
90264-X
McCrimmon, R. J., and Sherwin, R. S. (2010). Hypoglycemia in type 1 diabetes.
Diabetes 59, 2333–2339. doi: 10.2337/db10-0103
Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson,
M. A., et al. (2000). Loss of insulin signaling in hepatocytes leads to severe
insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87–97. doi:
10.1016/S1097-2765(00)00010-1
Moroz, N., Tong, M., Longato, L., Xu, H., and De La Monte, S. M. (2008). Limited
Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes
mellitus. J. Alzheimers. Dis. 15, 29–44.
Naik, R. G., and Palmer, J. P. (2007). “Latent autoimmune diabetes in adults,” in
Diabetes in Adults: Principles and Practice, eds S. Jabbour and E. A. Stephens
(London, GBR: Taylor & Francis), 288.
Neil, H. A., Dawson, J. A., and Baker, J. E. (1986). Risk of hypothermia in
elderly patients with diabetes. Br. Med. J. (Clin. Res. Ed). 293, 416–418. doi:
10.1136/bmj.293.6544.416
Ngarmukos, C., Baur, E. L., and Kumagai, A. K. (2001). Co-localization of GLUT1
and GLUT4 in the blood-brain barrier of the rat ventromedial hypothalamus.
Brain Res. 900, 1–8. doi: 10.1016/S0006-8993(01)02184-9
Nistico, R., Cavallucci, V., Piccinin, S., Macri, S., Pignatelli, M., Mehdawy, B., et al.
(2012). Insulin receptor beta-subunit haploinsufficiency impairs hippocampal
late-phase LTP and recognitionmemory.NeuromolecularMed. 14, 262–269. doi:
10.1007/s12017-012-8184-z
Nitsch, R., and Hoyer, S. (1991). Local action of the diabetogenic drug, streptozo-
tocin, on glucose and energy metabolism in rat brain cortex. Neurosci. Lett. 128,
199–202. doi: 10.1016/0304-3940(91)90260-Z
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 15
El Khoury et al. Insulin and Tau
Northam, E. A., Anderson, P. J., Jacobs, R., Hughes, M., Warne, G. L., and
Werther, G. A. (2001). Neuropsychological profiles of children with type
1 diabetes 6 years after disease onset. Diabetes Care 24, 1541–1546. doi:
10.2337/diacare.24.9.1541
Ott, A., Stolk, R. P., Van Harskamp, F., Pols, H. A., Hofman, A., and Breteler, M.
M. (1999). Diabetes mellitus and the risk of dementia: the Rotterdam study [see
comments]. Neurology 53, 1937–1942. doi: 10.1212/WNL.53.9.1937
Palop, J. J., Chin, J., and Mucke, L. (2006). A network dysfunction per-
spective on neurodegenerative diseases. Nature 443, 768–773. doi: 10.1038/
nature05289
Papon, M. A., El Khoury, N. B., Marcouiller, F., Julien, C., Morin, F., Bretteville,
A., et al. (2013). Deregulation of protein phosphatase 2A and hyperphospho-
rylation of tau protein following onset of diabetes in NOD mice. Diabetes 62,
609–617. doi: 10.2337/db12-0187
Papon, M. A., Whittington, R. A., El-Khoury, N. B., and Planel, E.
(2011). Alzheimer’s disease and anesthesia. Front. Neurosci. 4:272. doi:
10.3389/fnins.2010.00272
Pathan, A. R., Viswanad, B., Sonkusare, S. K., and Ramarao, P. (2006). Chronic
administration of pioglitazone attenuates intracerebroventricular streptozo-
tocin induced-memory impairment in rats. Life Sci. 79, 2209–2216. doi:
10.1016/j.lfs.2006.07.018
Perez, M., Ribe, E., Rubio, A., Lim, F., Moran, M. A., Ramos, P. G., et al.
(2005). Characterization of a double (amyloid precursor protein-tau) trans-
genic: tau phosphorylation and aggregation. Neuroscience 130, 339–347. doi:
10.1016/j.neuroscience.2004.09.029
Pirola, L., Johnston, A. M., and Van Obberghen, E. (2004). Modulation of insulin
action. Diabetologia 47, 170–184. doi: 10.1007/s00125-003-1313-3
Pistell, P. J., Morrison, C. D., Gupta, S., Knight, A. G., Keller, J. N., Ingram,
D. K., et al. (2010). Cognitive impairment following high fat diet consump-
tion is associated with brain inflammation. J. Neuroimmunol. 219, 25–32. doi:
10.1016/j.jneuroim.2009.11.010
Planel, E., Miyasaka, T., Launey, T., Chui, D. H., Tanemura, K., Sato, S., et al. (2004).
Alterations in glucose metabolism induce hypothermia leading to tau hyper-
phosphorylation through differential inhibition of kinase and phosphatase
activities: implications for Alzheimer’s disease. J. Neurosci. 24, 2401–2411. doi:
10.1523/JNEUROSCI.5561-03.2004
Planel, E., Richter, K. E., Nolan, C. E., Finley, J. E., Liu, L., Wen, Y., et al.
(2007a). Anesthesia leads to tau hyperphosphorylation through inhibition
of phosphatase activity by hypothermia. J. Neurosci. 27, 3090–3097. doi:
10.1523/JNEUROSCI.4854-06.2007
Planel, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M.,
et al. (2007b). Insulin dysfunction induces in vivo tau hyperphospho-
rylation through distinct mechanisms. J. Neurosci. 27, 13635–13648. doi:
10.1523/JNEUROSCI.3949-07.2007
Planel, E., Sun, X., and Takashima, A. (2002). Role of GSK-3 beta in
Alzheimer’s disease pathology. Drug Dev. Res. 56, 491–510. doi: 10.1002/
ddr.10100
Planel, E., Yasutake, K., Fujita, S. C., and Ishiguro, K. (2001). Inhibition of protein
phosphatase 2A overrides Tau protein kinase I / glycogen synthase kinase 3beta
and Cyclin-dependant kinase 5 inhibition and results in tau hyperphosphory-
lation in the hippocampus of starved mouse. J. Biol. Chem. 276, 34298–34306.
doi: 10.1074/jbc.M102780200
Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer,
P., et al. (2010). Insulin-resistant brain state after intracerebroventricular strep-
tozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-
overexpressing mice. J. Alzheimers. Dis. 19, 691–704. doi: 10.3233/JAD-2010-
1270
Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., and Davies, P. (2009).
Age-dependent impairment of cognitive and synaptic function in the
htau mouse model of tau pathology. J. Neurosci. 29, 10741–10749. doi:
10.1523/JNEUROSCI.1065-09.2009
Prickaerts, J., De Vente, J., Honig, W., Steinbusch, H., Ittersum, M. M. V., Blokland,
A., et al. (2000). Nitric oxide synthase does not mediate neurotoxicity after an
i.c.v. injection of streptozotocin in the rat. J. Neural. Transm. 107, 745–766. doi:
10.1007/s007020070056
Prickaerts, J., Fahrig, T., and Blokland, A. (1999). Cognitive performance and bio-
chemical markers in septum, hippocampus and striatum of rats after an i.c.v.
injection of streptozotocin: a correlation analysis. Behav. Brain Res. 102, 73–88.
doi: 10.1016/S0166-4328(98)00158-2
Qu, Z., Jiao, Z., Sun, X., Zhao, Y., Ren, J., and Xu, G. (2011). Effects of
streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain
Res. 1383, 300–306. doi: 10.1016/j.brainres.2011.01.084
Querfurth, H. W., and Laferla, F. M. (2010). Alzheimer’s disease. N. Engl. J. Med.
362, 329–344. doi: 10.1056/NEJMra0909142
Quintanilla, R. A., Orellana, D. I., Gonzalez-Billault, C., and Maccioni, R. B.
(2004). Interleukin-6 induces Alzheimer-type phosphorylation of tau pro-
tein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 295, 245–257. doi:
10.1016/j.yexcr.2004.01.002
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., and Ferreira, A. (2002).
Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci.
U.S.A. 99, 6364–6369. doi: 10.1073/pnas.092136199
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A.,
et al. (2008a). Intranasal insulin administration dose-dependently modulates
verbal memory and plasma amyloid-beta in memory-impaired older adults.
J. Alzheimers. Dis. 13, 323–331.
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L.
D., Cholerton, B., et al. (2008b). Intranasal insulin improves cognition
and modulates beta-amyloid in early AD. Neurology 70, 440–448. doi:
10.1212/01.WNL.0000265401.62434.36
Ribe, E. M., Perez, M., Puig, B., Gich, I., Lim, F., Cuadrado, M., et al. (2005).
Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss
in double mutant APP/tau transgenic mice. Neurobiol. Dis. 20, 814–822. doi:
10.1016/j.nbd.2005.05.027
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T.,
et al. (2007). Reducing endogenous tau ameliorates amyloid beta-induced
deficits in an Alzheimer’s disease mouse model. Science 316, 750–754. doi:
10.1126/science.1141736
Ronnemaa, E., Zethelius, B., Sundelof, J., Sundstrom, J., Degerman-
Gunnarsson, M., Berne, C., et al. (2008). Impaired insulin secretion
increases the risk of Alzheimer disease. Neurology 71, 1065–1071. doi:
10.1212/01.wnl.0000310646.32212.3a
Roriz-Filho, J. S., Sa-Roriz, T.M., Rosset, I., Camozzato, A. L., Santos, A. C., Chaves,
M. L., et al. (2009). (Pre)diabetes, brain aging, and cognition. Biochim. Biophys.
Acta. 1792, 432–443. doi: 10.1016/j.bbadis.2008.12.003
Saez, T. E., Pehar, M., Vargas, M., Barbeito, L., and Maccioni, R. B. (2004).
Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neu-
rons. In Vivo 18, 275–280.
Salkovic-Petrisic, M., and Hoyer, S. (2007). Central insulin resistance as a trig-
ger for sporadic Alzheimer-like pathology: an experimental approach. J. Neural
Transm. Suppl. 72, 217–233.
Salkovic-Petrisic, M., Tribl, F., Schmidt, M., Hoyer, S., and Riederer, P. (2006).
Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat
frontal cortex and hippocampus after damage to the insulin signalling pathway.
J. Neurochem. 96, 1005–1015. doi: 10.1111/j.1471-4159.2005.03637.x
Saravia, F. E., Revsin, Y., Gonzalez Deniselle, M. C., Gonzalez, S. L., Roig, P., Lima,
A., et al. (2002). Increased astrocyte reactivity in the hippocampus of murine
models of type 1 diabetes: the nonobese diabetic (NOD) and streptozotocin-
treated mice. Brain Res. 957, 345–353. doi: 10.1016/S0006-8993(02)03675-2
Sato, S., Tatebayashi, Y., Akagi, T., Chui, D. H., Murayama, M., Miyasaka, T.,
et al. (2002). Aberrant tau phosphorylation by glycogen synthase kinase-3beta
and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 277,
42060–42065. doi: 10.1074/jbc.M202241200
Schechter, R., Beju, D., and Miller, K. E. (2005). The effect of insulin deficiency on
tau and neurofilament in the insulin knockout mouse. Biochem. Biophys. Res.
Commun. 334, 979–986. doi: 10.1016/j.bbrc.2005.07.001
Schechter, R., Holtzclaw, L., Sadiq, F., Kahn, A., and Devaskar, S. (1988).
Insulin synthesis by isolated rabbit neurons. Endocrinology 123, 505–513. doi:
10.1210/endo-123-1-505
Schechter, R., Sadiq, H. F., and Devaskar, S. U. (1990). Insulin and insulin mRNA
are detected in neuronal cell cultures maintained in an insulin-free/serum-free
medium. J. Histochem. Cytochem. 38, 829–836. doi: 10.1177/38.6.2186089
Schoenle, E. J., Schoenle, D., Molinari, L., and Largo, R. H. (2002). Impaired intel-
lectual development in children with Type I diabetes: association with HbA(1c),
age at diagnosis and sex. Diabetologia 45, 108–114. doi: 10.1007/s125-002-
8250-6
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., et al. (2003).
Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau
phosphorylation. J. Neurosci. 23, 7084–7092.
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 16
El Khoury et al. Insulin and Tau
Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., et al.
(2004). Role for neuronal insulin resistance in neurodegenerative diseases. Proc.
Natl. Acad. Sci. U.S.A. 101, 3100–3105. doi: 10.1073/pnas.0308724101
Schulingkamp, R. J., Pagano, T. C., Hung, D., and Raffa, R. B. (2000). Insulin recep-
tors and insulin action in the brain: review and clinical implications. Neurosci.
Biobehav. Rev. 24, 855–872. doi: 10.1016/S0149-7634(00)00040-3
Scott, A. R., Bennett, T., and Macdonald, I. A. (1987). Diabetes mellitus and ther-
moregulation. Can. J. Physiol. Pharmacol. 65, 1365–1376. doi: 10.1139/y87-215
Selkoe, D. J. (2001). Alzheimer’s disease results from the cerebral accumulation and
cytotoxicity of amyloid beta-protein. J. Alzheimers. Dis. 3, 75–80.
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M. L., Grognet,
P., Bombois, S., et al. (2008). Biochemistry of Tau in Alzheimer’s disease
and related neurological disorders. Expert Rev. Proteomics 5, 207–224. doi:
10.1586/14789450.5.2.207
Shalaby, T. H., Yousef, M. K., and Dupre, R. K. (1989). Thermoregulatory responses
of diabetic rats. Comp. Biochem. Physiol. A 94, 153–157. doi: 10.1016/0300-
9629(89)90800-1
Sharma, M., and Gupta, Y. K. (2001). Intracerebroventricular injection of strep-
tozotocin in rats produces both oxidative stress in the brain and cognitive
impairment. Life Sci. 68, 1021–1029. doi: 10.1016/S0024-3205(00)01005-5
Shepherd, C. E., Thiel, E., McCann, H., Harding, A. J., and Halliday, G. M. (2000).
Cortical inflammation in Alzheimer disease but not dementia with Lewy bodies.
Arch. Neurol. 57, 817–822. doi: 10.1001/archneur.57.6.817
Sims-Robinson, C., Kim, B., Rosko, A., and Feldman, E. L. (2010). How does dia-
betes accelerate Alzheimer disease pathology? Nat. Rev. Neurol. 6, 551–559. doi:
10.1038/nrneurol.2010.130
Singh, B. S., Rajakumar, P. A., Eves, E. M., Rosner, M. R., Wainer, B. H., and
Devaskar, S. U. (1997). Insulin gene expression in immortalized rat hip-
pocampal and pheochromocytoma-12 cell lines. Regul. Pept. 69, 7–14. doi:
10.1016/S0167-0115(96)02120-9
Solas, M., Aisa, B., Tordera, R. M., Mugueta, M. C., and Ramirez, M. J. (2013).
Stress contributes to the development of central insulin resistance during aging:
implications for Alzheimer’s disease. Biochim. Biophys. Acta 1832, 2332–2339.
doi: 10.1016/j.bbadis.2013.09.013
Spranger, J., Kroke, A., Mohlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M.,
et al. (2003). Inflammatory cytokines and the risk to develop type 2 diabetes:
results of the prospective population-based European Prospective Investigation
into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812–817. doi:
10.2337/diabetes.52.3.812
Taha, C., and Klip, A. (1999). The insulin signaling pathway. J. Membr. Biol. 169,
1–12. doi: 10.1007/PL00005896
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D.,
et al. (2010). Diabetes-accelerated memory dysfunction via cerebrovascular
inflammation and Abeta deposition in an Alzheimer mouse model with dia-
betes. Proc. Natl. Acad. Sci. U.S.A. 107, 7036–7041. doi: 10.1073/pnas.1000
645107
Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al. (2012).
Demonstrated brain insulin resistance in Alzheimer’s disease patients is associ-
ated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin.
Invest. 122, 1316–1338. doi: 10.1172/JCI59903
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H.,
et al. (2008). Amyloid activates GSK-3beta to aggravate neuronal tauopa-
thy in bigenic mice. Am. J. Pathol. 172, 786–798. doi: 10.2353/ajpath.2008.
070904
Thambisetty, M., Jeffrey Metter, E., Yang, A., Dolan, H., Marano, C., Zonderman,
A. B., et al. (2013). Glucose intolerance, insulin resistance, and pathological fea-
tures of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA
Neurol. 70, 1167–1172. doi: 10.1001/jamaneurol.2013.284
Tian, Q., and Wang, J. (2002). Role of serine/threonine protein phosphatase in
Alzheimer’s disease. Neurosignals 11, 262–269. doi: 10.1159/000067425
Tirabassi, R. S., Flanagan, J. F., Wu, T., Kislauskis, E. H., Birckbichler, P. J.,
and Guberski, D. L. (2004). The BBZDR/Wor rat model for investigating
the complications of type 2 diabetes mellitus. ILAR J. 45, 292–302. doi:
10.1093/ilar.45.3.292
Tremblay, M. L., and Giguere, V. (2008). Phosphatases at the heart of FoxO
metabolic control. Cell Metab. 7, 101–103. doi: 10.1016/j.cmet.2008.01.004
Trojanowski, J. Q., and Lee, V. M. (1994). Paired helical filament tau in Alzheimer’s
disease. The kinase connection. Am. J. Pathol. 144, 449–453.
Unger, J. W., Livingston, J. N., andMoss, A. M. (1991). Insulin receptors in the cen-
tral nervous system: localization, signalling mechanisms and functional aspects.
Prog Neurobiol 36, 343–362. doi: 10.1016/0301-0082(91)90015-S
Van Der Heide, L. P., Kamal, A., Artola, A., Gispen, W. H., and Ramakers,
G. M. (2005). Insulin modulates hippocampal activity-dependent synaptic
plasticity in a N-methyl-d-aspartate receptor and phosphatidyl-inositol-3-
kinase-dependent manner. J. Neurochem. 94, 1158–1166. doi: 10.1111/j.1471-
4159.2005.03269.x
VanDer Jeugd, A., Ahmed, T., Burnouf, S., Belarbi, K., Hamdame,M., Grosjean,M.
E., et al. (2011). Hippocampal tauopathy in tau transgenic mice coincides with
impaired hippocampus-dependent learning and memory, and attenuated late-
phase long-term depression of synaptic transmission. Neurobiol. Learn. Mem.
95, 296–304. doi: 10.1016/j.nlm.2010.12.005
Veerendra Kumar, M. H., and Gupta, Y. K. (2003). Effect of Centella asiatica on cog-
nition and oxidative stress in an intracerebroventricular streptozotocin model
of Alzheimer’s disease in rats. Clin. Exp. Pharmacol. Physiol. 30, 336–342. doi:
10.1046/j.1440-1681.2003.03842.x
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., and Lee, V. M. (2001).
PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease
hippocampus. Exp. Neurol. 168, 402–412. doi: 10.1006/exnr.2001.7630
Wallum, B. J., Taborsky, G. J. Jr., Porte, D. Jr., Figlewicz, D. P., Jacobson, L., Beard,
J. C., et al. (1987). Cerebrospinal fluid insulin levels increase during intra-
venous insulin infusions in man. J. Clin. Endocrinol. Metab. 64, 190–194. doi:
10.1210/jcem-64-1-190
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975). A
protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U.S.A.
72, 1858–1862. doi: 10.1073/pnas.72.5.1858
White, M. F. (1997). The insulin signalling system and the IRS proteins.
Diabetologia 40 Suppl 2, S2–17. doi: 10.1007/s001250051387
White, M. F. (2003). Insulin signaling in health and disease. Science 302, 1710–1711.
doi: 10.1126/science.1092952
Whittington, R. A., Virag, L., Marcouiller, F., Papon, M. A., El Khoury, N. B., Julien,
C., et al. (2011). Propofol directly increases tau phosphorylation. PLoS ONE
6:e16648. doi: 10.1371/journal.pone.0016648
Wilcock, G. K., and Esiri, M. M. (1982). Plaques, tangles and dementia. A quanti-
tative study. J. Neurol. Sci. 56, 343–356. doi: 10.1016/0022-510X(82)90155-1
Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global prevalence of
diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27,
1047–1053. doi: 10.2337/diacare.27.5.1047
Withers, D. J., Burks, D. J., Towery, H. H., Altamuro, S. L., Flint, C. L., and White,
M. F. (1999). Irs-2 coordinates Igf-1 receptor-mediated beta-cell development
and peripheral insulin signalling. Nat. Genet. 23, 32–40. doi: 10.1038/12631
Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., et al.
(1998). Disruption of IRS-2 causes type 2 diabetes inmice.Nature 391, 900–904.
doi: 10.1038/36116
Xu, W. L., Qiu, C. X., Wahlin, A., Winblad, B., and Fratiglioni, L. (2004).
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year
follow-up study. Neurology 63, 1181–1186. doi: 10.1212/01.WNL.0000140291.
86406.D1
Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., et al. (2013). Subcutaneous
administration of liraglutide ameliorates Alzheimer-associated tau hyperphos-
phorylation in rats with type 2 diabetes. J. Alzheimers. Dis. 37, 637–648. doi:
10.3233/JAD-130491
Yoon, S. Y., Park, J. S., Choi, J. E., Choi, J. M., Lee, W. J., Kim, S. W., et al. (2010).
Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocam-
pus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol.
Dis. 40, 449–455. doi: 10.1016/j.nbd.2010.07.005
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido,
T. C., et al. (2007). Synapse loss and microglial activation precede tan-
gles in a P301S tauopathy mouse model. Neuron 53, 337–351. doi:
10.1016/j.neuron.2007.01.010
Youngren, J. F. (2007). Regulation of insulin receptor function. Cell. Mol. Life Sci.
64, 873–891. doi: 10.1007/s00018-007-6359-9
Yun, S. W., Gartner, U., Arendt, T., and Hoyer, S. (2000). Increase in vulnerability
of middle-aged rat brain to lead by cerebral energy depletion. Brain Res. Bull.
52, 371–378. doi: 10.1016/S0361-9230(00)00274-4
Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M. J., et al. (1999).
Brain insulin receptors and spatial memory. Correlated changes in gene
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 17
El Khoury et al. Insulin and Tau
expression, tyrosine phosphorylation, and signaling molecules in the hip-
pocampus of water maze trained rats. J. Biol. Chem. 274, 34893–34902. doi:
10.1074/jbc.274.49.34893
Zhao, W., Wu, X., Xie, H., Ke, Y., and Yung, W. H. (2010). Permissive role of insulin
in the expression of long-term potentiation in the hippocampus of immature
rats. Neurosignals. 18, 236–245. doi: 10.1159/000324040
Zhao, W. Q., and Alkon, D. L. (2001). Role of insulin and insulin receptor in
learning and memory. Mol. Cell. Endocrinol. 177, 125–134. doi: 10.1016/S0303-
7207(01)00455-5
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 27 November 2013; paper pending published: 11 December 2013; accepted:
16 January 2014; published online: 11 February 2014.
Citation: El Khoury NB, Gratuze M, Papon M-A, Bretteville A and Planel E (2014)
Insulin dysfunction and Tau pathology. Front. Cell. Neurosci. 8:22. doi: 10.3389/fncel.
2014.00022
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 El Khoury, Gratuze, Papon, Bretteville and Planel. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 22 | 18
